<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta http-equiv="Content-Style-Type" content="text/css" />
		<meta name="generator" content="MediaWiki 1.15alpha" />
		<meta name="keywords" content="Atherosclerosis,Articles with unsourced statements since October 2008,Vascular diseases,Congenital vascular defects,Vascular tumors,ACE inhibitor,Abdominal aortic aneurysm,American Diabetes Association,American Heart Association,Aneurysm,Angina pectoris" />
		<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Atherosclerosis&amp;action=edit" />
		<link rel="edit" title="Edit this page" href="/w/index.php?title=Atherosclerosis&amp;action=edit" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
		<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=rss" />
		<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
		<title>Atherosclerosis - Wikipedia, the free encyclopedia</title>
		<link rel="stylesheet" href="/skins-1.5/common/shared.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/common/commonPrint.css?207xx" type="text/css" media="print" />
		<link rel="stylesheet" href="/skins-1.5/monobook/main.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/chick/main.css?207xx" type="text/css" media="handheld" />
		<!--[if lt IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE50Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE55Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 6]><link rel="stylesheet" href="/skins-1.5/monobook/IE60Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 7]><link rel="stylesheet" href="/skins-1.5/monobook/IE70Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Common.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Print.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="print" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Handheld.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="handheld" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Monobook.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=-&amp;action=raw&amp;maxage=2678400&amp;gen=css" type="text/css" />
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?207xx"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->

		<script type= "text/javascript">/*<![CDATA[*/
		var skin = "monobook";
		var stylepath = "/skins-1.5";
		var wgArticlePath = "/wiki/$1";
		var wgScriptPath = "/w";
		var wgScript = "/w/index.php";
		var wgVariantArticlePath = false;
		var wgActionPaths = {};
		var wgServer = "http://en.wikipedia.org";
		var wgCanonicalNamespace = "";
		var wgCanonicalSpecialPageName = false;
		var wgNamespaceNumber = 0;
		var wgPageName = "Atherosclerosis";
		var wgTitle = "Atherosclerosis";
		var wgAction = "view";
		var wgArticleId = "85385";
		var wgIsArticle = true;
		var wgUserName = null;
		var wgUserGroups = null;
		var wgUserLanguage = "en";
		var wgContentLanguage = "en";
		var wgBreakFrames = false;
		var wgCurRevisionId = 281569196;
		var wgVersion = "1.15alpha";
		var wgEnableAPI = true;
		var wgEnableWriteAPI = true;
		var wgSeparatorTransformTable = ["", ""];
		var wgDigitTransformTable = ["", ""];
		var wgMWSuggestTemplate = "http://en.wikipedia.org/w/api.php?action=opensearch\x26search={searchTerms}\x26namespace={namespaces}\x26suggest";
		var wgDBname = "enwiki";
		var wgSearchNamespaces = [0];
		var wgMWSuggestMessages = ["with suggestions", "no suggestions"];
		var wgRestrictionEdit = [];
		var wgRestrictionMove = [];
		/*]]>*/</script>

		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?207xx"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?207xx"></script>
		<script type="text/javascript" src="/skins-1.5/common/mwsuggest.js?207xx"></script>
<script type="text/javascript">/*<![CDATA[*/
var wgNotice='';var wgNoticeLocal='';
/*]]>*/</script>		<script type="text/javascript" src="http://upload.wikimedia.org/centralnotice/wikipedia/en/centralnotice.js?207xx"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
	</head>
<body class="mediawiki ltr ns-0 ns-subject page-Atherosclerosis skin-monobook">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
		<div id="siteNotice"><script type='text/javascript'>if (wgNotice != '') document.writeln(wgNotice);</script></div>		<h1 id="firstHeading" class="firstHeading">Atherosclerosis</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table class="infobox" width="200" cellspacing="0" style="font-size: 95%; text-align:left">
<tr>
<td style="text-align: center; background: lightgrey; font-size: 95%;" colspan="2"><b>Atherosclerosis</b><br />
<i>Classification and external resources</i></td>
</tr>
<tr>
<th colspan="2" style="text-align: center; font-size: smaller;">
<div class="center">
<div class="floatnone"><a href="/wiki/File:Endo_dysfunction_Athero.PNG" class="image" title="Endo dysfunction Athero.PNG"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/9/9a/Endo_dysfunction_Athero.PNG/190px-Endo_dysfunction_Athero.PNG" width="190" height="209" border="0" /></a></div>
</div>
</th>
</tr>
<tr style="line-height: 1;">
<td colspan="2" style="text-align:center;"><small>Changes in endothelial dysfunction in atherosclerosis (note text comments about geometry error)</small></td>
</tr>
<tr>
<th><a href="/wiki/ICD" title="ICD" class="mw-redirect">ICD</a>-<a href="/wiki/List_of_ICD-10_codes" title="List of ICD-10 codes" class="mw-redirect">10</a></th>
<td><a href="/wiki/ICD-10_Chapter_I" title="ICD-10 Chapter I" class="mw-redirect">I</a><a href="http://www.who.int/classifications/apps/icd/icd10online/?gi70.htm+i70" class="external text" title="http://www.who.int/classifications/apps/icd/icd10online/?gi70.htm+i70" rel="nofollow">70.</a></td>
</tr>
<tr>
<th><a href="/wiki/ICD" title="ICD" class="mw-redirect">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9</a></th>
<td><a href="http://www.icd9data.com/getICD9Code.ashx?icd9=440" class="external text" title="http://www.icd9data.com/getICD9Code.ashx?icd9=440" rel="nofollow">440</a></td>
</tr>
<tr>
<th><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a href="http://www.diseasesdatabase.com/ddb1039.htm" class="external text" title="http://www.diseasesdatabase.com/ddb1039.htm" rel="nofollow">1039</a></td>
</tr>
<tr>
<th><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a href="http://www.nlm.nih.gov/medlineplus/ency/article/000171.htm" class="external text" title="http://www.nlm.nih.gov/medlineplus/ency/article/000171.htm" rel="nofollow">000171</a></td>
</tr>
<tr>
<th><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a href="http://www.emedicine.com/med/topic182.htm" class="external text" title="http://www.emedicine.com/med/topic182.htm" rel="nofollow">med/182</a>&#160;</td>
</tr>
<tr>
<th><b><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></b></th>
<td><a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?field=uid&amp;term=D050197" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?field=uid&amp;term=D050197" rel="nofollow">D050197</a></td>
</tr>
</table>
<p><b>Atherosclerosis</b> is a <a href="/wiki/Syndrome" title="Syndrome">syndrome</a> affecting <a href="/wiki/Artery" title="Artery">arterial</a> <a href="/wiki/Blood_vessel" title="Blood vessel">blood vessels</a>. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of <a href="/wiki/Macrophage" title="Macrophage">macrophage</a> <a href="/wiki/White_blood_cells" title="White blood cells" class="mw-redirect">white blood cells</a> and promoted by low density (especially small particle) <a href="/wiki/Lipoproteins" title="Lipoproteins" class="mw-redirect">lipoproteins</a> (plasma proteins that carry <a href="/wiki/Cholesterol" title="Cholesterol">cholesterol</a> and <a href="/wiki/Triglycerides" title="Triglycerides" class="mw-redirect">triglycerides</a>) without adequate removal of fats and cholesterol from the macrophages by functional <a href="/wiki/High_density_lipoprotein" title="High density lipoprotein" class="mw-redirect">high density lipoproteins</a> (HDL), (see <a href="/wiki/ApoA-1_Milano" title="ApoA-1 Milano">apoA-1 Milano</a>). It is commonly referred to as a hardening or furring of the arteries. It is caused by the formation of multiple <a href="/wiki/Atheroma" title="Atheroma">plaques</a> within the <a href="/wiki/Arteries" title="Arteries" class="mw-redirect">arteries</a>.<sup id="cite_ref-0" class="reference"><a href="#cite_note-0" title=""><span>[</span>1<span>]</span></a></sup></p>
<p>The <b><a href="/wiki/Atheroma" title="Atheroma">atheromatous plaque</a></b> is divided into three distinct components:</p>
<ol>
<li>The <a href="/wiki/Atheroma" title="Atheroma">atheroma</a> ("lump of porridge", from <i>Athera</i>, <a href="/wiki/Porridge" title="Porridge">porridge</a> in Greek,), which is the nodular accumulation of a soft, flaky, yellowish material at the center of large plaques, composed of <a href="/wiki/Macrophage" title="Macrophage">macrophages</a> nearest the <a href="/wiki/Lumen_(anatomy)" title="Lumen (anatomy)">lumen</a> of the artery</li>
<li>Underlying areas of <a href="/wiki/Cholesterol" title="Cholesterol">cholesterol</a> crystals</li>
<li>Calcification at the outer base of older/more advanced lesions.</li>
</ol>
<p>The following terms are similar, yet distinct, in both spelling and meaning, and can be easily confused: <a href="/wiki/Arteriosclerosis" title="Arteriosclerosis">arteriosclerosis</a>, arteriolosclerosis, and atherosclerosis. <b>Arteriosclerosis</b> is a general term describing any hardening (and loss of elasticity) of medium or large arteries (from the Greek <b>Arterio</b>, meaning <i>artery</i>, and <i>sclerosis</i>, meaning <i>hardening</i>); <b>arteriolosclerosis</b> is any hardening (and loss of elasticity) of <a href="/wiki/Arteriole" title="Arteriole">arterioles</a> (small arteries); <b>atherosclerosis</b> is a hardening of an artery specifically due to an atheromatous plaque. Therefore, atherosclerosis is a form of arteriosclerosis.</p>
<p>Atherosclerosis, though typically asymptomatic for decades, eventually produces two main problems: <b>First</b>, the <a href="/wiki/Atheroma" title="Atheroma">atheromatous plaques</a>, though long compensated for by artery enlargement (see <a href="/wiki/Intima-media_thickness" title="Intima-media thickness">IMT</a>), eventually lead to <a href="/wiki/Vulnerable_plaque" title="Vulnerable plaque">plaque ruptures</a> and clots inside the artery <a href="/wiki/Lumen_(anatomy)" title="Lumen (anatomy)">lumen</a> over the ruptures. The clots heal and usually shrink but leave behind <a href="/wiki/Stenosis" title="Stenosis">stenosis</a> (narrowing) of the artery (both locally and in smaller downstream branches), or worse, complete closure, and, therefore, an insufficient blood supply to the tissues and organ it feeds. <b>Second</b>, if the compensating artery enlargement process is excessive, then a net <a href="/wiki/Aneurysm" title="Aneurysm">aneurysm</a> results.</p>
<p>These complications of advanced atherosclerosis are chronic, slowly progressive and cumulative. Most commonly, soft plaque suddenly ruptures (see <a href="/wiki/Vulnerable_plaque" title="Vulnerable plaque">vulnerable plaque</a>), causing the formation of a <a href="/wiki/Thrombus" title="Thrombus">thrombus</a> that will rapidly slow or stop blood flow, leading to death of the tissues fed by the artery in approximately 5 minutes. This catastrophic event is called an <a href="/wiki/Infarction" title="Infarction">infarction</a>. One of the most common recognized scenarios is called <a href="/wiki/Coronary_thrombosis" title="Coronary thrombosis">coronary thrombosis</a> of a <a href="/wiki/Coronary_artery" title="Coronary artery" class="mw-redirect">coronary artery</a>, causing <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">myocardial infarction</a> (a heart attack). Even worse is the same process in an artery to the brain, commonly called <a href="/wiki/Stroke" title="Stroke">stroke</a>. Another common scenario in very advanced disease is <a href="/wiki/Claudication" title="Claudication">claudication</a> from insufficient blood supply to the legs, typically due to a combination of both stenosis and aneurysmal segments narrowed with <a href="/wiki/Thrombus" title="Thrombus">clots</a>. Since atherosclerosis is a body-wide process, similar events occur also in the arteries to the brain, intestines, kidneys, legs, etc.</p>
<p>Yet, many infarctions involve only very small amounts of tissue and are termed <a href="/wiki/Clinically_silent" title="Clinically silent">clinically silent</a>, because the person having the infarction does not notice the problem, does not seek medical help or when they do, physicians do not recognize what has happened.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Causes"><span class="tocnumber">1</span> <span class="toctext">Causes</span></a></li>
<li class="toclevel-1"><a href="#Symptoms"><span class="tocnumber">2</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-1"><a href="#Atherogenesis"><span class="tocnumber">3</span> <span class="toctext">Atherogenesis</span></a>
<ul>
<li class="toclevel-2"><a href="#Cellular"><span class="tocnumber">3.1</span> <span class="toctext">Cellular</span></a></li>
<li class="toclevel-2"><a href="#Calcification_and_lipids"><span class="tocnumber">3.2</span> <span class="toctext">Calcification and lipids</span></a></li>
<li class="toclevel-2"><a href="#Visible_features"><span class="tocnumber">3.3</span> <span class="toctext">Visible features</span></a></li>
<li class="toclevel-2"><a href="#Rupture_and_stenosis"><span class="tocnumber">3.4</span> <span class="toctext">Rupture and stenosis</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Diagnosis_of_plaque-related_disease"><span class="tocnumber">4</span> <span class="toctext">Diagnosis of plaque-related disease</span></a></li>
<li class="toclevel-1"><a href="#Physiologic_factors_that_increase_risk"><span class="tocnumber">5</span> <span class="toctext">Physiologic factors that increase risk</span></a>
<ul>
<li class="toclevel-2"><a href="#Modifiable"><span class="tocnumber">5.1</span> <span class="toctext">Modifiable</span></a></li>
<li class="toclevel-2"><a href="#Nonmodifiable"><span class="tocnumber">5.2</span> <span class="toctext">Nonmodifiable</span></a></li>
<li class="toclevel-2"><a href="#Lesser_or_uncertain"><span class="tocnumber">5.3</span> <span class="toctext">Lesser or uncertain</span></a></li>
<li class="toclevel-2"><a href="#Dietary_risk_factors"><span class="tocnumber">5.4</span> <span class="toctext">Dietary risk factors</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Prognosis"><span class="tocnumber">6</span> <span class="toctext">Prognosis</span></a></li>
<li class="toclevel-1"><a href="#Treatment"><span class="tocnumber">7</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2"><a href="#Statins"><span class="tocnumber">7.1</span> <span class="toctext">Statins</span></a>
<ul>
<li class="toclevel-3"><a href="#Primary_and_secondary_prevention"><span class="tocnumber">7.1.1</span> <span class="toctext">Primary and secondary prevention</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Diet_and_dietary_supplements"><span class="tocnumber">7.2</span> <span class="toctext">Diet and dietary supplements</span></a></li>
<li class="toclevel-2"><a href="#Surgical_intervention"><span class="tocnumber">7.3</span> <span class="toctext">Surgical intervention</span></a></li>
<li class="toclevel-2"><a href="#Prophylaxis"><span class="tocnumber">7.4</span> <span class="toctext">Prophylaxis</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Recent_research"><span class="tocnumber">8</span> <span class="toctext">Recent research</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#Footnotes"><span class="tocnumber">10</span> <span class="toctext">Footnotes</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Causes" id="Causes"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=1" title="Edit section: Causes">edit</a>]</span> <span class="mw-headline">Causes</span></h2>
<p>Atherosclerosis develops from low-density lipoprotein molecules (LDL) becoming oxidized (ldl-ox) by free radicals, particularly oxygen free radicals (ROS). Blood in arteries contains plenty of oxygen and is where atherosclerosis develops. Blood in veins contains little oxygen where atherosclerosis rarely develops. When oxidized LDL comes in contact with an artery wall, a series of reactions occur to repair the damage to the artery wall caused by oxidized LDL. The LDL molecule is globular shaped with a hollow core to carry cholesterol throughout the body to generate brain tissues, vitamin D, and so on. Cholesterol does not dissolve in water. Blood is 70% water. Cholesterol can move in the bloodstream only by being transported by LDL.</p>
<p>The body's immune system responds to the damage to the artery wall caused by oxidized LDL by sending specialized white blood cells (<a href="/wiki/Macrophages" title="Macrophages" class="mw-redirect">macrophages</a> and <a href="/wiki/T-lymphocytes" title="T-lymphocytes" class="mw-redirect">T-lymphocytes</a>) to absorb the oxidized-LDL forming specialized <a href="/wiki/Foam_cells" title="Foam cells">foam cells</a>. Unfortunately, these white blood cells are not able to process the oxidized-LDL, and ultimately grow then rupture, depositing a greater amount of oxidized cholesterol into the artery wall. This triggers more white blood cells, continuing the cycle.</p>
<p>Eventually, the artery becomes inflamed. The cholesterol plaque causes the muscle cells to enlarge and form a hard cover over the affected area. This hard cover is what causes a narrowing of the artery, reduces the blood flow and increases blood pressure.</p>
<p>Some researchers believe that atherosclerosis may be caused by an infection of the vascular smooth muscle cells. Chickens, for example, develop atherosclerosis when infected with the <a href="/wiki/Marek%27s_disease" title="Marek's disease">Marek's disease</a> herpesvirus.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1" title=""><span>[</span>2<span>]</span></a></sup> <a href="/wiki/Herpesvirus" title="Herpesvirus" class="mw-redirect">Herpesvirus</a> infection of arterial <a href="/wiki/Smooth_muscle_cells" title="Smooth muscle cells" class="mw-redirect">smooth muscle cells</a> has been shown to cause cholesteryl ester (CE) accumulation.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2" title=""><span>[</span>3<span>]</span></a></sup> <a href="/wiki/Cholesteryl_ester" title="Cholesteryl ester">Cholesteryl ester</a> accumulation is associated with atherosclerosis.</p>
<p><a name="Symptoms" id="Symptoms"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=2" title="Edit section: Symptoms">edit</a>]</span> <span class="mw-headline">Symptoms</span></h2>
<p>Atherosclerosis typically begins in early adolescence, and is usually found in most major <a href="/wiki/Artery" title="Artery">arteries</a>, yet is asymptomatic and not detected by most diagnostic methods during life. The stage immediately prior to actual atherosclerosis is known as subclinical atherosclerosis. The majority of the process leading to subclinical atherosclerosis can happen without our knowing it, especially given the large variety of risk factors.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3" title=""><span>[</span>4<span>]</span></a></sup> Autopsies of healthy young men who died during the Korean and Vietnam Wars showed evidence of the disease.<sup id="cite_ref-pmid11390341_4-0" class="reference"><a href="#cite_note-pmid11390341-4" title=""><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-5" class="reference"><a href="#cite_note-5" title=""><span>[</span>6<span>]</span></a></sup> It most commonly becomes seriously symptomatic when interfering with the <a href="/wiki/Coronary_circulation" title="Coronary circulation">coronary circulation</a> supplying the <a href="/wiki/Heart" title="Heart">heart</a> or <a href="/wiki/Cerebral_circulation" title="Cerebral circulation">cerebral circulation</a> supplying the <a href="/wiki/Brain" title="Brain">brain</a>, and is considered the most important underlying cause of <a href="/wiki/Cerebrovascular_accident" title="Cerebrovascular accident" class="mw-redirect">strokes</a>, <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">heart attacks</a>, various <a href="/wiki/Heart_disease" title="Heart disease">heart diseases</a> including <a href="/wiki/Congestive_heart_failure" title="Congestive heart failure" class="mw-redirect">congestive heart failure</a>, and most <a href="/wiki/Cardiovascular_disease" title="Cardiovascular disease">cardiovascular diseases</a>, in general. Atheroma in arm, or more often in leg arteries, which produces decreased blood flow is called <a href="/wiki/Peripheral_artery_occlusive_disease" title="Peripheral artery occlusive disease" class="mw-redirect">peripheral artery occlusive disease</a> (PAOD).</p>
<p>According to United States data for the year 2004, for about 65% of men and 47% of women, the first <a href="/wiki/Symptom" title="Symptom">symptom</a> of atherosclerotic <a href="/wiki/Cardiovascular_disease" title="Cardiovascular disease">cardiovascular disease</a> is <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">heart attack</a> or <a href="/wiki/Sudden_cardiac_death" title="Sudden cardiac death">sudden cardiac death</a> (death within one hour of onset of the symptom).</p>
<p>Most artery flow disrupting events occur at locations with less than 50% <a href="/wiki/Lumen_(anatomy)" title="Lumen (anatomy)">lumen</a> narrowing (~20% <a href="/wiki/Stenosis" title="Stenosis">stenosis</a> is average). [The reader might reflect that the illustration above, like most illustrations of arterial disease, overemphasizes lumen narrowing, as opposed to compensatory external diameter enlargement (at least within smaller arteries, e.g., heart arteries) typical of the atherosclerosis process as it progresses, see Glagov<sup id="cite_ref-Glagov_6-0" class="reference"><a href="#cite_note-Glagov-6" title=""><span>[</span>7<span>]</span></a></sup> and the ASTEROID trial,<sup id="cite_ref-Nissen_7-0" class="reference"><a href="#cite_note-Nissen-7" title=""><span>[</span>8<span>]</span></a></sup> the <a href="/wiki/IVUS" title="IVUS" class="mw-redirect">IVUS</a> photographs on page 8, as examples for a more accurate understanding. The relative geometry error within the illustration is common to many older illustrations, an error slowly being more commonly recognized within the last decade.]</p>
<p><a href="/wiki/Cardiac_stress_test" title="Cardiac stress test">Cardiac stress testing</a>, traditionally the most commonly performed non-invasive testing method for blood flow limitations, in general, detects only <a href="/wiki/Lumen_(anatomy)" title="Lumen (anatomy)">lumen</a> narrowing of ~75% or greater, although some physicians claim that nuclear stress methods can detect as little as 50%.</p>
<p><a name="Atherogenesis" id="Atherogenesis"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=3" title="Edit section: Atherogenesis">edit</a>]</span> <span class="mw-headline">Atherogenesis</span></h2>
<p>Atherogenesis is the developmental process of atheromatous plaques. It is characterized by a remodeling of <a href="/wiki/Artery" title="Artery">arteries</a> involving the concomitant accumulation of fatty substances called plaques. One recent theory suggests that, for unknown reasons, <a href="/wiki/Leukocytes" title="Leukocytes" class="mw-redirect">leukocytes</a>, such as <a href="/wiki/Monocytes" title="Monocytes" class="mw-redirect">monocytes</a> or <a href="/wiki/Basophils" title="Basophils" class="mw-redirect">basophils</a>, begin to attack the <a href="/wiki/Endothelium" title="Endothelium">endothelium</a> of the artery lumen in <a href="/wiki/Cardiac_muscle" title="Cardiac muscle">cardiac muscle</a>. The ensuing <a href="/wiki/Inflammation" title="Inflammation">inflammation</a> leads to formation of atheromatous plaques in the arterial <a href="/wiki/Tunica_intima" title="Tunica intima">tunica intima</a>, a region of the vessel wall located between the <a href="/wiki/Endothelium" title="Endothelium">endothelium</a> and the <a href="/wiki/Tunica_media" title="Tunica media">tunica media</a>. The bulk of these lesions is made of excess fat, <a href="/wiki/Collagen" title="Collagen">collagen</a>, and <a href="/wiki/Elastin" title="Elastin">elastin</a>. At first, as the plaques grow, only <a href="/wiki/Intima-media_thickness" title="Intima-media thickness">wall thickening</a> occurs without any narrowing, stenosis of the artery opening, called the lumen; <a href="/wiki/Stenosis" title="Stenosis">stenosis</a> is a late event, which may never occur and is often the result of repeated plaque rupture and healing responses, not just the atherosclerosis process by itself.</p>
<p><a name="Cellular" id="Cellular"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=4" title="Edit section: Cellular">edit</a>]</span> <span class="mw-headline">Cellular</span></h3>
<p>The first step of atherogenesis is the development of so called "<a href="/wiki/Fatty_streak" title="Fatty streak">fatty streak</a>"s, which are small sub-endothelial deposits of monocyte-derived macrophages. The primary documented driver of this process is oxidized Lipoprotein particles within the wall, beneath the <a href="/wiki/Endothelium" title="Endothelium">endothelial</a> cells, though upper normal or elevated concentrations of blood glucose also plays a major role and not all factors are fully understood. Fatty streaks may appear and disappear.</p>
<p>Low Density Lipoprotein particles in blood plasma, when they invade the <a href="/wiki/Endothelium" title="Endothelium">endothelium</a> and become <a href="/wiki/Oxidize" title="Oxidize" class="mw-redirect">oxidize</a> creates a risk for <a href="/wiki/Cardiovascular_disease" title="Cardiovascular disease">cardiovascular disease</a>. A complex set of biochemical reactions regulates the oxidation of LDL, chiefly stimulated by presence of enzymes, e.g. <a href="/w/index.php?title=Lp-LpA2&amp;action=edit&amp;redlink=1" class="new" title="Lp-LpA2 (page does not exist)">Lp-LpA2</a> and <a href="/wiki/Free_radical" title="Free radical" class="mw-redirect">free radicals</a> in the <a href="/wiki/Endothelium" title="Endothelium">endothelium</a> or blood vessel lining.</p>
<p>The initial damage to the blood vessel wall results in a "call for help," an inflammatory response. <a href="/wiki/Monocyte" title="Monocyte">Monocytes</a> (a type of <a href="/wiki/White_blood_cell" title="White blood cell">white blood cell</a>) enter the artery wall from the bloodstream, with platelets adhering to the area of insult. This may be promoted by <a href="/wiki/Redox_signaling" title="Redox signaling">redox signaling</a> induction of factors such as <a href="/wiki/VCAM-1" title="VCAM-1">VCAM-1</a>, which recruit circulating monocytes. The <a href="/wiki/Monocyte" title="Monocyte">monocytes</a> differentiate <a href="/wiki/Macrophage" title="Macrophage">macrophages</a>, which ingest <a href="/wiki/Oxidize" title="Oxidize" class="mw-redirect">oxidized</a> <a href="/wiki/LDL" title="LDL" class="mw-redirect">LDL</a>, slowly turning into large "foam cells" – so-described because of their changed appearance resulting from the numerous internal cytoplasmic <a href="/wiki/Vesicle_(biology)" title="Vesicle (biology)">vesicles</a> and resulting high <a href="/wiki/Lipid" title="Lipid">lipid</a> content. Under the microscope, the lesion now appears as a fatty streak. Foam cells eventually die, and further propagate the inflammatory process. There is also smooth muscle proliferation and migration from tunica media to intima responding to cytokines secreted by damaged endothelial cells. This would cause the formation of a fibrous capsule covering the fatty streak.</p>
<p><a name="Calcification_and_lipids" id="Calcification_and_lipids"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=5" title="Edit section: Calcification and lipids">edit</a>]</span> <span class="mw-headline">Calcification and lipids</span></h3>
<p>Intracellular <a href="/wiki/Calcification" title="Calcification">microcalcifications</a> form within <a href="/wiki/Vascular_smooth_muscle" title="Vascular smooth muscle">vascular smooth muscle</a> cells of the surrounding muscular layer, specifically in the muscle cells adjacent to the atheromas. In time, as cells die, this leads to extracellular calcium deposits between the muscular wall and outer portion of the atheromatous plaques. A similar form of an intramural calcification, presenting the picture of an early phase of arteriosclerosis, appears to be induced by a number of drugs that have an antiproliferative mechanism of action (<a href="/wiki/Rainer_Liedtke" title="Rainer Liedtke">Rainer Liedtke</a> 2008).</p>
<p>Cholesterol is delivered into the vessel wall by cholesterol-containing <a href="/wiki/Low-density_lipoprotein" title="Low-density lipoprotein">low-density lipoprotein</a> (LDL) particles. To attract and stimulate macrophages, the cholesterol must be released from the LDL particles and oxidized, a key step in the ongoing inflammatory process. The process is worsened if there is insufficient <a href="/wiki/High-density_lipoprotein" title="High-density lipoprotein">high-density lipoprotein</a> (HDL), the lipoprotein particle that removes cholesterol from tissues and carries it back to the liver.</p>
<p>The foam cells and platelets encourage the migration and proliferation of <a href="/wiki/Smooth_muscle" title="Smooth muscle">smooth muscle</a> cells, which in turn ingest lipids, become replaced by collagen and transform into foam cells themselves. A protective fibrous cap normally forms between the fatty deposits and the artery lining (the <a href="/wiki/Endothelium" title="Endothelium">intima</a>).</p>
<p>These capped fatty deposits (now called 'atheromas') produce enzymes that cause the artery to enlarge over time. As long as the artery enlarges sufficiently to compensate for the extra thickness of the atheroma, then no narrowing ("<a href="/wiki/Stenosis" title="Stenosis">stenosis</a>") of the opening ("lumen") occurs. The artery becomes expanded with an egg-shaped cross-section, still with a circular opening. If the enlargement is beyond proportion to the atheroma thickness, then an <a href="/wiki/Aneurysm" title="Aneurysm">aneurysm</a> is created.<sup id="cite_ref-Glagov_6-1" class="reference"><a href="#cite_note-Glagov-6" title=""><span>[</span>7<span>]</span></a></sup></p>
<p><a name="Visible_features" id="Visible_features"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=6" title="Edit section: Visible features">edit</a>]</span> <span class="mw-headline">Visible features</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:232px;"><a href="/wiki/File:Atherosclerosis,_aorta,_gross_pathology_PHIL_846_lores.jpg" class="image" title="Severe atherosclerosis of the aorta. Autopsy specimen."><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/f/f1/Atherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg/230px-Atherosclerosis%2C_aorta%2C_gross_pathology_PHIL_846_lores.jpg" width="230" height="358" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Atherosclerosis,_aorta,_gross_pathology_PHIL_846_lores.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Severe atherosclerosis of the <a href="/wiki/Aorta" title="Aorta">aorta</a>. <a href="/wiki/Autopsy" title="Autopsy">Autopsy</a> specimen.</div>
</div>
</div>
<p>Although arteries are not typically studied microscopically, two plaque types can be distinguished<a href="http://www.pathologyatlas.ro/coronary-atherosclerosis-fibrous-plaque.php" class="external autonumber" title="http://www.pathologyatlas.ro/coronary-atherosclerosis-fibrous-plaque.php" rel="nofollow">[1]</a>:</p>
<ol>
<li>The <b>fibro-lipid (fibro-fatty) plaque</b> is characterized by an accumulation of lipid-laden cells underneath the intima of the arteries, typically without narrowing the lumen due to compensatory expansion of the bounding muscular layer of the artery wall. Beneath the endothelium there is a "fibrous cap" covering the atheromatous "core" of the plaque. The core consists of lipid-laden cells (macrophages and smooth muscle cells) with elevated tissue cholesterol and cholesterol ester content, fibrin, proteoglycans, collagen, elastin, and cellular debris. In advanced plaques, the central core of the plaque usually contains extracellular cholesterol deposits (released from dead cells), which form areas of cholesterol crystals with empty, needle-like clefts. At the periphery of the plaque are younger "foamy" cells and capillaries. These plaques usually produce the most damage to the individual when they rupture.</li>
<li>The <b>fibrous plaque</b> is also localized under the intima, within the wall of the artery resulting in thickening and expansion of the wall and, sometimes, spotty localized narrowing of the lumen with some atrophy of the muscular layer. The fibrous plaque contains collagen fibers (eosinophilic), precipitates of calcium (hematoxylinophilic) and, rarely, lipid-laden cells.</li>
</ol>
<p>In effect, the muscular portion of the artery wall forms small <a href="/wiki/Aneurysm" title="Aneurysm">aneurysms</a> just large enough to hold the <a href="/wiki/Atheroma" title="Atheroma">atheroma</a> that are present. The muscular portion of artery walls usually remain strong, even after they have remodeled to compensate for the <a href="/wiki/Atheroma" title="Atheroma">atheromatous</a> plaques.</p>
<p>However, <a href="/wiki/Atheroma" title="Atheroma">atheromas</a> within the vessel wall are soft and fragile with little elasticity. Arteries constantly expand and contract with each heartbeat, i.e., the pulse. In addition, the calcification deposits between the outer portion of the atheroma and the muscular wall, as they progress, lead to a loss of elasticity and stiffening of the artery as a whole.</p>
<p>The calcification deposits, after they have become sufficiently advanced, are partially visible on coronary artery <a href="/wiki/Computed_tomography" title="Computed tomography">computed tomography</a> or <a href="/wiki/Electron_beam_tomography" title="Electron beam tomography">electron beam tomography</a> (EBT) as rings of increased radiographic density, forming halos around the outer edges of the atheromatous plaques, within the artery wall. On CT, &gt;130 units on the <a href="/wiki/Hounsfield_scale" title="Hounsfield scale">Hounsfield scale</a> {some argue for 90 units) has been the radiographic density usually accepted as clearly representing tissue calcification within arteries. These deposits demonstrate unequivocal evidence of the disease, relatively advanced, even though the lumen of the artery is often still normal by angiographic or <a href="/wiki/Intravascular_ultrasound" title="Intravascular ultrasound">intravascular ultrasound</a>.</p>
<p><a name="Rupture_and_stenosis" id="Rupture_and_stenosis"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=7" title="Edit section: Rupture and stenosis">edit</a>]</span> <span class="mw-headline">Rupture and stenosis</span></h3>
<p>Although the disease process tends to be slowly progressive over decades, it usually remains asymptomatic until an atheroma obstructs the bloodstream in the artery. This is typically by rupture of an atheroma, clotting and fibrous organization of the clot within the lumen, covering the rupture but also producing <a href="/wiki/Stenosis" title="Stenosis">stenosis</a>, or over time and after repeated ruptures, resulting in a persistent, usually localized stenosis. Stenoses can be slowly progressive, whereas plaque rupture is a sudden event that occurs specifically in atheromas with thinner/weaker fibrous caps that have become "unstable."</p>
<p>Repeated plaque ruptures, ones not resulting in total lumen closure, combined with the clot patch over the rupture and healing response to stabilize the clot, is the process that produces most stenoses over time. The stenotic areas tend to become more stable, despite increased flow velocities at these narrowings. Most major blood-flow-stopping events occur at large plaques, which, prior to their rupture, produced very little if any stenosis.</p>
<p>From clinical trials, 20% is the average stenosis at plaques that subsequently rupture with resulting complete artery closure. Most severe clinical events do not occur at plaques that produce high-grade stenosis. From clinical trials, only 14% of heart attacks occur from artery closure at plaques producing a 75% or greater stenosis prior to the vessel closing.</p>
<p>If the fibrous cap separating a soft atheroma from the bloodstream within the artery ruptures, tissue fragments are exposed and released, and blood enters the atheroma within the wall and sometimes results in a sudden expansion of the atheroma size. Tissue fragments are very clot-promoting, containing <a href="/wiki/Collagen" title="Collagen">collagen</a> and <a href="/wiki/Tissue_factor" title="Tissue factor">tissue factor</a>; they activate <a href="/wiki/Platelet" title="Platelet">platelets</a> and activate the <a href="/wiki/Coagulation" title="Coagulation">system of coagulation</a>. The result is the formation of a <a href="/wiki/Thrombus" title="Thrombus">thrombus</a> (blood clot) overlying the atheroma, which obstructs blood flow acutely. With the obstruction of blood flow, downstream tissues are starved of <a href="/wiki/Oxygen" title="Oxygen">oxygen</a> and nutrients. If this is the <a href="/wiki/Myocardium" title="Myocardium" class="mw-redirect">myocardium</a> (heart muscle), <a href="/wiki/Angina_pectoris" title="Angina pectoris">angina</a> (cardiac chest pain) or <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">myocardial infarction</a> (heart attack) develops.</p>
<p><a name="Diagnosis_of_plaque-related_disease" id="Diagnosis_of_plaque-related_disease"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=8" title="Edit section: Diagnosis of plaque-related disease">edit</a>]</span> <span class="mw-headline">Diagnosis of plaque-related disease</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Calcificatio_atherosclerotica.jpg" class="image" title="Microphotography of arterial wall with calcified (violet colour) atherosclerotic plaque (haematoxillin &amp; eosin stain)"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/4/49/Calcificatio_atherosclerotica.jpg/180px-Calcificatio_atherosclerotica.jpg" width="180" height="145" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Calcificatio_atherosclerotica.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Microphotography of arterial wall with calcified (violet colour) atherosclerotic plaque (haematoxillin &amp; eosin stain)</div>
</div>
</div>
<p>Areas of severe narrowing, <a href="/wiki/Stenosis" title="Stenosis">stenosis</a>, detectable by angiography, and to a lesser extent "<a href="/wiki/Stress_testing" title="Stress testing">stress testing</a>" have long been the focus of human diagnostic techniques for <a href="/wiki/Cardiovascular_disease" title="Cardiovascular disease">cardiovascular disease</a>, in general. However, these methods focus on detecting only severe <a href="/wiki/Stenosis" title="Stenosis">narrowing</a>, not the underlying atherosclerosis disease. As demonstrated by human clinical studies, most severe events occur in locations with heavy plaque, yet little or no lumen <a href="/wiki/Stenosis" title="Stenosis">narrowing</a> present before debilitating events suddenly occur. Plaque rupture can lead to artery lumen occlusion within seconds to minutes, and potential permanent debility and sometimes sudden death.</p>
<p>Plaques that have ruptured are called complicated plaques. The lipid matrix breaks through the thinning <a href="/wiki/Collagen" title="Collagen">collagen</a> gap and when the lipids come in contact with the blood, clotting occurs. After rupture the platelet adhesion causes the clotting cascade to contact with the lipid pool causing a <a href="/wiki/Thrombus" title="Thrombus">thrombus</a> to form. This thrombus will eventually grow and travel throughout the body. The <a href="/wiki/Thrombus" title="Thrombus">thrombus</a> will travel through different arteries and veins and eventually become lodged in an area that narrows. Once the area is blocked, blood and <a href="/wiki/Oxygen" title="Oxygen">oxygen</a> will not be able to supply the vessels and will cause death of cells and lead to <a href="/wiki/Necrosis" title="Necrosis">necrosis</a> and poisoning. Serious complicated plaques can cause death of organ tissues, causing serious complications to that organ system.</p>
<p>Greater than 75% lumen <a href="/wiki/Stenosis" title="Stenosis">stenosis</a> used to be considered by cardiologists as the hallmark of clinically significant disease because it is typically only at this severity of narrowing of the larger heart arteries that recurring episodes of <a href="/wiki/Angina_pectoris" title="Angina pectoris">angina</a> and detectable abnormalities by <a href="/wiki/Stress_test" title="Stress test" class="mw-redirect">stress testing</a> methods are seen. However, clinical trials have shown that only about 14% of clinically-debilitating events occur at locations with this, or greater severity of <a href="/wiki/Stenosis" title="Stenosis">narrowing</a>. The majority of events occur due to atheroma plaque rupture at areas without <a href="/wiki/Stenosis" title="Stenosis">narrowing</a> sufficient enough to produce any <a href="/wiki/Angina_pectoris" title="Angina pectoris">angina</a> or <a href="/wiki/Stress_test" title="Stress test" class="mw-redirect">stress test</a> abnormalities. Thus, since the later-1990s, greater attention is being focused on the "vulnerable plaque."<sup id="cite_ref-MaseriFuster_8-0" class="reference"><a href="#cite_note-MaseriFuster-8" title=""><span>[</span>9<span>]</span></a></sup></p>
<p>Though any artery in the body can be involved, usually only severe <a href="/wiki/Stenosis" title="Stenosis">narrowing</a> or obstruction of some arteries, those that supply more critically-important organs are recognized. Obstruction of arteries supplying the heart muscle result in a <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">heart attack</a>. Obstruction of arteries supplying the brain result in a <a href="/wiki/Stroke" title="Stroke">stroke</a>. These events are life-changing, and often result in irreversible loss of function because lost heart muscle and brain cells do not grow back to any significant extent, typically less than 2%.</p>
<p>Over the last couple of decades, methods other than angiography and stress-testing have been increasingly developed as ways to better detect atherosclerotic disease before it becomes symptomatic. These have included both (a) anatomic detection methods and (b) physiologic measurement methods.</p>
<p>Examples of anatomic methods include: (1) coronary calcium scoring by CT, (2) carotid IMT (<a href="/wiki/Intima-media_thickness" title="Intima-media thickness">intimal media thickness</a>) measurement by ultrasound, and (3) IVUS.</p>
<p>Examples of physiologic methods include: (1) lipoprotein subclass analysis, (2) <a href="/wiki/Glycosylated_hemoglobin" title="Glycosylated hemoglobin">HbA1c</a>, (3) <a href="/wiki/C-reactive_protein" title="C-reactive protein">hs-CRP</a>, and (4) <a href="/wiki/Homocysteine" title="Homocysteine">homocysteine</a>.</p>
<p>The example of the metabolic syndrome combines both anatomic (abdominal girth) and physiologic (blood pressure, elevated blood glucose) methods.</p>
<p>Advantages of these two approaches: The anatomic methods directly measure some aspect of the actual atherosclerotic disease process itself, thus offer potential for earlier detection, including before symptoms start, disease staging and tracking of disease progression. The physiologic methods are often less expensive and safer and changing them for the better may slow disease progression, in some cases with marked improvement.</p>
<p>Disadvantages of these two approaches: The anatomic methods are generally more expensive and several are invasive, such as IVUS. The physiologic methods do not quantify the current state of the disease or directly track progression. For both, clinicians and third party payers have been slow to accept the usefulness of these newer approaches.</p>
<p><a name="Physiologic_factors_that_increase_risk" id="Physiologic_factors_that_increase_risk"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=9" title="Edit section: Physiologic factors that increase risk">edit</a>]</span> <span class="mw-headline">Physiologic factors that increase risk</span></h2>
<p>Various anatomic, physiological &amp; behavioral risk factors for atherosclerosis are known.<sup id="cite_ref-Blankenhorn_9-0" class="reference"><a href="#cite_note-Blankenhorn-9" title=""><span>[</span>10<span>]</span></a></sup> These can be divided into various categories: congenital <i>vs</i> acquired, modifiable or not, classical or non-classical. The points labelled '+' in the following list form the core components of "<a href="/wiki/Metabolic_syndrome" title="Metabolic syndrome">metabolic syndrome</a>".</p>
<p>Factors add to each other multiplicatively, with two factors increasing the risk of atherosclerosis fourfold.<sup id="cite_ref-Kumar345_10-0" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup> Hyperlipidemia, hypertension and cigarette smoking together increases the risk seven times.<sup id="cite_ref-Kumar345_10-1" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></p>
<p><a name="Modifiable" id="Modifiable"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=10" title="Edit section: Modifiable">edit</a>]</span> <span class="mw-headline">Modifiable</span></h3>
<ul>
<li>Having <b><a href="/wiki/Diabetes" title="Diabetes" class="mw-redirect">diabetes</a></b><sup id="cite_ref-Kumar345_10-2" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup> or <a href="/wiki/Impaired_glucose_tolerance" title="Impaired glucose tolerance">Impaired glucose tolerance</a> (IGT) +</li>
<li><b><a href="/wiki/Lipoprotein" title="Lipoprotein">Dyslipoproteinemia</a></b><sup id="cite_ref-Kumar345_10-3" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup> (unhealthy patterns of serum proteins carrying fats &amp; <a href="/wiki/Cholesterol" title="Cholesterol">cholesterol</a>): +
<ul>
<li>High serum concentration of <a href="/wiki/Low-density_lipoprotein" title="Low-density lipoprotein">low-density lipoprotein</a> (LDL, "bad if elevated concentrations and small"), and / or <a href="/wiki/Very_low_density_lipoprotein" title="Very low density lipoprotein" class="mw-redirect">very low density lipoprotein</a> (VLDL) particles, i.e., "lipoprotein subclass analysis"</li>
<li>Low serum concentration of functioning <a href="/wiki/High_density_lipoprotein" title="High density lipoprotein" class="mw-redirect">high density lipoprotein</a> (HDL "protective if large and high enough" particles), i.e., "lipoprotein subclass analysis"</li>
<li>An LDL:HDL ratio greater than 3:1</li>
</ul>
</li>
<li><b><a href="/wiki/Tobacco_smoking" title="Tobacco smoking">Tobacco smoking</a></b>, increases risk by 200% after several <a href="/wiki/Pack_year" title="Pack year">pack years</a> <sup id="cite_ref-Kumar345_10-4" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Having <b><a href="/wiki/Hypertension" title="Hypertension">high</a> <a href="/wiki/Blood_pressure" title="Blood pressure">blood pressure</a></b> +, on its own increasing risk by 60%<sup id="cite_ref-Kumar345_10-5" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Elevated serum <b><a href="/wiki/C-reactive_protein" title="C-reactive protein">C-reactive protein</a> concentrations</b><sup id="cite_ref-Kumar345_10-6" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
</ul>
<p><a name="Nonmodifiable" id="Nonmodifiable"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=11" title="Edit section: Nonmodifiable">edit</a>]</span> <span class="mw-headline">Nonmodifiable</span></h3>
<ul>
<li><a href="/wiki/Senescence" title="Senescence">Advanced age</a> <sup id="cite_ref-Kumar345_10-7" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li><a href="/wiki/Male" title="Male">Male</a> sex<sup id="cite_ref-Kumar345_10-8" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Having close relatives who have had some complication of atherosclerosis (eg. <a href="/wiki/Coronary_heart_disease" title="Coronary heart disease" class="mw-redirect">coronary heart disease</a> or <a href="/wiki/Stroke" title="Stroke">stroke</a>)<sup id="cite_ref-Kumar345_10-9" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Genetic abnormalities,<sup id="cite_ref-Kumar345_10-10" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup> e.g. <a href="/wiki/Familial_hypercholesterolemia" title="Familial hypercholesterolemia">familial hypercholesterolemia</a></li>
</ul>
<p><a name="Lesser_or_uncertain" id="Lesser_or_uncertain"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=12" title="Edit section: Lesser or uncertain">edit</a>]</span> <span class="mw-headline">Lesser or uncertain</span></h3>
<p>The following factors are of relatively lesser importance, are uncertain or nonquantitated:</p>
<ul>
<li>Being <a href="/wiki/Obesity" title="Obesity">obese</a><sup id="cite_ref-Kumar345_10-11" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup> (in particular <a href="/wiki/Central_obesity" title="Central obesity" class="mw-redirect">central obesity</a>, also referred to as <i>abdominal</i> or <i>male-type</i> obesity) +</li>
<li>A <a href="/wiki/Sedentary_lifestyle" title="Sedentary lifestyle">sedentary lifestyle</a><sup id="cite_ref-Kumar345_10-12" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li><a href="/wiki/Postmenopausal_estrogen_deficiency" title="Postmenopausal estrogen deficiency" class="mw-redirect">Postmenopausal estrogen deficiency</a><sup id="cite_ref-Kumar345_10-13" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>High carbohydrate intake<sup id="cite_ref-Kumar345_10-14" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Intake of <a href="/wiki/Trans_fat" title="Trans fat">trans fat</a><sup id="cite_ref-Kumar345_10-15" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Elevated serum levels of <a href="/wiki/Triglycerides" title="Triglycerides" class="mw-redirect">triglycerides</a> +</li>
<li>Elevated serum levels of <a href="/wiki/Homocysteine" title="Homocysteine">homocysteine</a></li>
<li>Elevated serum levels of <a href="/wiki/Uric_acid" title="Uric acid">uric acid</a> (also responsible for gout)</li>
<li>Elevated serum <a href="/wiki/Fibrinogen" title="Fibrinogen" class="mw-redirect">fibrinogen</a> concentrations</li>
<li>Elevated serum <a href="/wiki/Lipoprotein(a)" title="Lipoprotein(a)">lipoprotein(a)</a> concentrations <sup id="cite_ref-Kumar345_10-16" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
<li>Chronic systemic <a href="/wiki/Inflammation" title="Inflammation">inflammation</a> as reflected by upper normal WBC concentrations, elevated <a href="/wiki/C_reactive_protein" title="C reactive protein" class="mw-redirect">hs-CRP</a> and many other blood chemistry markers, most only research level at present, not clinically done.<sup id="cite_ref-Bhatt_11-0" class="reference"><a href="#cite_note-Bhatt-11" title=""><span>[</span>12<span>]</span></a></sup></li>
<li><a href="/wiki/Stress_(medicine)" title="Stress (medicine)" class="mw-redirect">Stress</a><sup id="cite_ref-Kumar345_10-17" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup> or symptoms of <a href="/wiki/Clinical_depression" title="Clinical depression" class="mw-redirect">clinical depression</a></li>
<li><a href="/wiki/Hyperthyroidism" title="Hyperthyroidism">Hyperthyroidism</a> (an over-active <a href="/wiki/Thyroid" title="Thyroid">thyroid</a>)</li>
<li>Elevated serum insulin levels + <sup id="cite_ref-Hyperinsulinaemia_12-0" class="reference"><a href="#cite_note-Hyperinsulinaemia-12" title=""><span>[</span>13<span>]</span></a></sup></li>
<li>Short sleep duration <sup id="cite_ref-13" class="reference"><a href="#cite_note-13" title=""><span>[</span>14<span>]</span></a></sup></li>
<li><a href="/wiki/Chlamydia_pneumoniae" title="Chlamydia pneumoniae" class="mw-redirect">Chlamydia pneumoniae</a> infection<sup id="cite_ref-Kumar345_10-18" class="reference"><a href="#cite_note-Kumar345-10" title=""><span>[</span>11<span>]</span></a></sup></li>
</ul>
<p><a name="Dietary_risk_factors" id="Dietary_risk_factors"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=13" title="Edit section: Dietary risk factors">edit</a>]</span> <span class="mw-headline">Dietary risk factors</span></h3>
<p>The relation between dietary fat and atherosclerosis is a contentious field. The <a href="/wiki/United_States_Department_of_Agriculture" title="United States Department of Agriculture">USDA</a>, in its <a href="/wiki/Food_pyramid" title="Food pyramid">food pyramid</a>, promotes a low-fat diet, based largely on its view that fat in the diet is atherogenic. The <a href="/wiki/American_Heart_Association" title="American Heart Association">American Heart Association</a>, the <a href="/wiki/American_Diabetes_Association" title="American Diabetes Association">American Diabetes Association</a> and the <a href="/wiki/National_Cholesterol_Education_Program" title="National Cholesterol Education Program">National Cholesterol Education Program</a> make similar recommendations. In contrast, Prof <a href="/wiki/Walter_Willett" title="Walter Willett">Walter Willett</a> (Harvard School of Public Health, <a href="/wiki/Principal_investigator" title="Principal investigator">PI</a> of the second <a href="/wiki/Nurses%27_Health_Study" title="Nurses' Health Study">Nurses' Health Study</a>) recommends much higher levels, especially of <a href="/wiki/Monounsaturated_fat" title="Monounsaturated fat">monounsaturated</a> and <a href="/wiki/Polyunsaturated_fat" title="Polyunsaturated fat">polyunsaturated fat</a>.<sup id="cite_ref-titleFood_Pyramids:_Nutrition_Source.2C_Harvard_School_of_Public_Health_14-0" class="reference"><a href="#cite_note-titleFood_Pyramids:_Nutrition_Source.2C_Harvard_School_of_Public_Health-14" title=""><span>[</span>15<span>]</span></a></sup> Writing in <a href="/wiki/Science" title="Science">Science</a>, <a href="/wiki/Gary_Taubes" title="Gary Taubes">Gary Taubes</a> detailed that political considerations played into the recommendations of government bodies.<sup id="cite_ref-Taubes_15-0" class="reference"><a href="#cite_note-Taubes-15" title=""><span>[</span>16<span>]</span></a></sup> These differing views reach a consensus, though, against consumption of <a href="/wiki/Trans_fat" title="Trans fat">trans fats</a>.</p>
<p>The role of dietary oxidized fats / <a href="/wiki/Lipid_peroxidation" title="Lipid peroxidation">lipid peroxidation</a> (<a href="/wiki/Rancidification" title="Rancidification">rancid fats</a>) in humans is not clear. Laboratory animals fed rancid fats develop atherosclerosis. Rats fed <a href="/wiki/Docosahexaenoic_acid" title="Docosahexaenoic acid">DHA</a>-containing oils experienced marked disruptions to their <a href="/wiki/Antioxidant" title="Antioxidant">antioxidant</a> systems, as well as accumulated significant amounts of peroxide in their blood, livers and kidneys.<sup id="cite_ref-SongJH_16-0" class="reference"><a href="#cite_note-SongJH-16" title=""><span>[</span>17<span>]</span></a></sup> In another study, rabbits fed atherogenic diets containing various oils were found to undergo the greatest amount of oxidative susceptibility of LDL via polyunsaturated oils.<sup id="cite_ref-YapSC_17-0" class="reference"><a href="#cite_note-YapSC-17" title=""><span>[</span>18<span>]</span></a></sup> In a study involving rabbits fed heated soybean oil, "grossly induced atherosclerosis and marked liver damage were histologically and clinically demonstrated".<sup id="cite_ref-Greco_18-0" class="reference"><a href="#cite_note-Greco-18" title=""><span>[</span>19<span>]</span></a></sup></p>
<p>Rancid fats and oils taste very bad even in small amounts; people avoid eating them.<sup id="cite_ref-pmid16249011_19-0" class="reference"><a href="#cite_note-pmid16249011-19" title=""><span>[</span>20<span>]</span></a></sup> It is very difficult to measure or estimate the actual human consumption of these substances.<sup id="cite_ref-pmid12589185_20-0" class="reference"><a href="#cite_note-pmid12589185-20" title=""><span>[</span>21<span>]</span></a></sup> In addition, the majority of oils consumed in the United States are refined, bleached, deodorized and degummed by manufacturers. The resultant oils are colorless, odorless, tasteless and have a longer shelf life than their unrefined counterparts.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21" title=""><span>[</span>22<span>]</span></a></sup> This extensive processing serves to make peroxidated, rancid oils much more elusive to detection via the various human senses than the unprocessed alternatives.</p>
<p>The <a href="/wiki/French_paradox" title="French paradox">French paradox</a> is the observation that despite having a diet similar to those United States in terms of fat intake, rates of heart disease are lower in <a href="/wiki/France" title="France">France</a>. There is evidence to suggest the French paradox is due to underestimation of the rates of heart disease in France.<sup id="cite_ref-die_22-0" class="reference"><a href="#cite_note-die-22" title=""><span>[</span>23<span>]</span></a></sup></p>
<p><br />
<a href="/wiki/Homogenization" title="Homogenization">Homogenization</a> of dairy is another contributing factor to atherosclerosis because during homogenization the fat globules in the milk are reduced in size and encapsulated into liposomes, which pass through the stomach undigested. (The liposomes are protected from the digestive acids.) Because of the tiny size of the fat globules after the milk has been homogenized, the liposomes are then able to pass into the bloodstream through the walls of the intestines, which is where the damage occurs. The liposomes contain a partially destroyed enzyme called <a href="/wiki/Xanthine_oxidase" title="Xanthine oxidase">xanthine oxidase</a>, better known as XO. XO is only found in the liver, unless a person drinks homogenized milk. Then it is found in the liposomes that enter the bloodstream, where it begins to attack <a href="/wiki/Plasmalogen" title="Plasmalogen">plasmalogen</a>. (Plasmalogen makes up 30% of the membrane system in human heart muscle cells.) XO can only either use the plasmalogen or destroy it, and in most autopsies of people who have died from heart and circulatory disease <a href="/wiki/Plasmalogen" title="Plasmalogen">plasmalogen</a> is missing, arterial inner linings are eaten away, and mineral deposits covered in fat and <a href="/wiki/Cholesterol" title="Cholesterol">cholesterol</a> create a deadly plaque in the arteries. The addition of synthetic <a href="/wiki/Vitamin_D" title="Vitamin D">vitamin D</a> in the milk actually exacerbates the activity of XO. <sup id="cite_ref-23" class="reference"><a href="#cite_note-23" title=""><span>[</span>24<span>]</span></a></sup></p>
<p><a name="Prognosis" id="Prognosis"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=14" title="Edit section: Prognosis">edit</a>]</span> <span class="mw-headline">Prognosis</span></h2>
<p><a href="/wiki/Dyslipidemia" title="Dyslipidemia">Lipoprotein imbalances</a>, upper normal and especially elevated blood sugar, i.e., <a href="/wiki/Diabetes" title="Diabetes" class="mw-redirect">diabetes</a> and high blood pressure are risk factors for atherosclerosis; <a href="/wiki/Homocysteine" title="Homocysteine">homocysteine</a>, stopping smoking, taking <a href="/wiki/Anticoagulant" title="Anticoagulant">anticoagulants</a> (anti-clotting agents), which target clotting factors, taking omega-3 oils from fatty fish or plant oils such as flax or canola oils, exercising and losing weight are the usual focus of treatments that have proven to be helpful in clinical trials. The target serum cholesterol level is ideally equal or less than 4mmol/L (160 mg/dL), and triglycerides equal or less than 2mmol/L (180 mg/dL).</p>
<p>Evidence has increased that people with <a href="/wiki/Diabetes" title="Diabetes" class="mw-redirect">diabetes</a>, despite their not having clinically-detectable atherosclotic disease, have more severe debility from atherosclerotic events over time than even non-diabetics that have already suffered atherosclerotic events. Thus <a href="/wiki/Diabetes" title="Diabetes" class="mw-redirect">diabetes</a> has been upgraded to be viewed as an advanced atherosclerotic disease equivalent.</p>
<p><a name="Treatment" id="Treatment"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=15" title="Edit section: Treatment">edit</a>]</span> <span class="mw-headline">Treatment</span></h2>
<p>If atherosclerosis leads to symptoms, some symptoms such as <a href="/wiki/Angina_pectoris" title="Angina pectoris">angina pectoris</a> can be treated. Non-pharmaceutical means are usually the first method of treatment, such as cessation of smoking and practicing regular exercise. If these methods do not work, medicines are usually the next step in treating cardiovascular diseases, and, with improvements, have increasingly become the most effective method over the long term. However, medicines are criticized for their expense, patented control and occasional undesired effects.</p>
<p><a name="Statins" id="Statins"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=16" title="Edit section: Statins">edit</a>]</span> <span class="mw-headline">Statins</span></h3>
<p>In general, the group of medications referred to as <a href="/wiki/Statins" title="Statins" class="mw-redirect">statins</a> has been the most popular and are widely prescribed for treating atherosclerosis. They have relatively few short-term or longer-term undesirable side-effects, and multiple comparative treatment/<a href="/wiki/Placebo-controlled_studies" title="Placebo-controlled studies">placebo trials</a> have fairly consistently shown strong effects in reducing atherosclerotic disease 'events' and generally ~25% comparative mortality reduction in clinical trials, although one study design, ALLHAT,<sup id="cite_ref-pmid12479764_24-0" class="reference"><a href="#cite_note-pmid12479764-24" title=""><span>[</span>25<span>]</span></a></sup> was less strongly favorable.</p>
<p>The newest statin, <a href="/wiki/Rosuvastatin" title="Rosuvastatin">rosuvastatin</a>, has been the first to demonstrate regression of atherosclerotic plaque within the <a href="/wiki/Coronary_arteries" title="Coronary arteries" class="mw-redirect">coronary arteries</a> by <a href="/wiki/IVUS" title="IVUS" class="mw-redirect">IVUS</a> (intravascular ultrasound evaluation).<sup id="cite_ref-Nissen_7-1" class="reference"><a href="#cite_note-Nissen-7" title=""><span>[</span>8<span>]</span></a></sup> The study was set up to demonstrate effect primarily on atherosclerosis volume within a 2 year time-frame in people with active/symptomatic disease (angina frequency also declined markedly) but not global clinical outcomes, which was expected to require longer trial time periods; these longer trials remain in progress.</p>
<p>However, for most people, changing their physiologic behaviors, from the usual high risk to greatly reduced risk, requires a combination of several compounds, taken on a daily basis and indefinitely. More and more human treatment trials have been done and are ongoing that demonstrate improved outcome for those people using more-complex and effective treatment regimens that change physiologic behaviour patterns to more closely resemble those that humans exhibit in childhood at a time before <a href="/wiki/Fatty_streaks" title="Fatty streaks" class="mw-redirect">fatty streaks</a> begin forming.</p>
<p>The <a href="/wiki/Statin" title="Statin">statins</a>, and some other medications, have been shown to have <a href="/wiki/Antioxidant" title="Antioxidant">antioxidant</a> effects, possibly part of their basis for some of their therapeutic success in reducing cardiac 'events'.</p>
<p>The success of statin drugs in clinical trials is based on some reductions in mortality rates, however by trial design biased toward men and middle-age, the data is as, as yet, less strongly clear for women and people over the age of 70<sup id="cite_ref-25" class="reference"><a href="#cite_note-25" title=""><span>[</span>26<span>]</span></a></sup>. For example, in the <a href="/wiki/Scandinavian_Simvastatin_Survival_Study" title="Scandinavian Simvastatin Survival Study">Scandinavian Simvastatin Survival Study (4S)</a>, the first large placebo controlled, randomized clinical trial of a statin in people with advanced disease who had already suffered a heart attack, the overall mortality rate reduction for those taking the statin, vs. placebo, was 30%. For the subgroup of people in the trial that had Diabetes Mellitus, the mortality rate reduction between statin and placebo was 54%. 4S was a 5.4-year trial that started in 1989 and was published in 1995 after completion. There were 3 more dead women at trial's end on statin than in the group on placebo drug whether chance or some relation to the statin remains unclear. The ASTEROID trial has been the first to show actual disease volume regression<sup id="cite_ref-Nissen_7-2" class="reference"><a href="#cite_note-Nissen-7" title=""><span>[</span>8<span>]</span></a></sup> (see page 8 of the paper, which shows cross-sectional areas of the total heart artery wall at start and 2 years of rosuvastatin 40 mg/day treatment); however, its design was not able to "prove" the mortality reduction issue since it did not include a placebo group, the individuals offered treatment within the trial had advanced disease and promoting a comparison placebo arm was judged to be unethical.</p>
<p><a name="Primary_and_secondary_prevention" id="Primary_and_secondary_prevention"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=17" title="Edit section: Primary and secondary prevention">edit</a>]</span> <span class="mw-headline">Primary and secondary prevention</span></h4>
<p>Combinations of <a href="/wiki/Statin" title="Statin">statins</a>, <a href="/wiki/Niacin" title="Niacin">niacin</a>, intestinal cholesterol absorption-inhibiting supplements (<a href="/wiki/Ezetimibe" title="Ezetimibe">ezetimibe</a> and others, and to a much lesser extent <a href="/wiki/Fibrate" title="Fibrate">fibrates</a>) have been the most successful in changing common but sub-optimal <a href="/wiki/Lipoprotein" title="Lipoprotein">lipoprotein</a> patterns and group outcomes. In the many secondary prevention and several primary prevention trials, several classes of lipoprotein expression (less correctly termed "cholesterol-lowering") altering agents have consistently reduced not only heart attack, stroke and hospitalization but also all-cause mortality rates. The first of the large secondary prevention comparative statin/placebo treatment trials was the Scandinavian Simvastatin Survival Study. (4S) <sup id="cite_ref-26" class="reference"><a href="#cite_note-26" title=""><span>[</span>27<span>]</span></a></sup> with over 15 more extending through the more recent ASTEROID <sup id="cite_ref-ASTEROID_27-0" class="reference"><a href="#cite_note-ASTEROID-27" title=""><span>[</span>28<span>]</span></a></sup> trial published in 2006. The first primary prevention comparative treatment trial was AFCAPS/TexCAPS <sup id="cite_ref-CAPS_28-0" class="reference"><a href="#cite_note-CAPS-28" title=""><span>[</span>29<span>]</span></a></sup> with multiple later comparative statin/placebo treatment trials including EXCEL.<sup id="cite_ref-pmid1985608_29-0" class="reference"><a href="#cite_note-pmid1985608-29" title=""><span>[</span>30<span>]</span></a></sup>, ASCOT<sup id="cite_ref-pmid15855581_30-0" class="reference"><a href="#cite_note-pmid15855581-30" title=""><span>[</span>31<span>]</span></a></sup> and SPARCL.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31" title=""><span>[</span>32<span>]</span></a></sup> <sup id="cite_ref-32" class="reference"><a href="#cite_note-32" title=""><span>[</span>33<span>]</span></a></sup> While the statin trials have all been clearly favorable for improved human outcomes, only ASTEROID showed evidence of atherosclerotic regression (slight). For both human and animal trials, those which have shown evidence of disease regression had all utilized more aggressive combination agent treatment strategies, nearly always including niacin.<sup id="cite_ref-Blankenhorn_9-1" class="reference"><a href="#cite_note-Blankenhorn-9" title=""><span>[</span>10<span>]</span></a></sup></p>
<p><a name="Diet_and_dietary_supplements" id="Diet_and_dietary_supplements"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=18" title="Edit section: Diet and dietary supplements">edit</a>]</span> <span class="mw-headline">Diet and dietary supplements</span></h3>
<p>Vitamin B3, AKA <a href="/wiki/Niacin" title="Niacin">niacin</a>, in pharmacologic doses, (generally 1,000 to 3,000 mg/day), sold in many OTC and prescription formulations, tends to improve (a) HDL levels, size and function, (b) shift LDL particle distribution to larger particle size and (c) lower <a href="/wiki/Lipoprotein(a)" title="Lipoprotein(a)">lipoprotein(a)</a>, an atherosclerosis promoting genetic variant of LDL. Additionally, individual responses to daily niacin, while mostly evident after a month at effective doses, tends to continue to slowly improve further over time. (However, careful patient understanding of how to achieve this without nuisance symptoms is needed, though not often achieved.) Research work on increasing HDL particle concentration and function, beyond the usual niacin effect/response, even more important, is slowly advancing.</p>
<p>Dietary changes to achieve benefit have been more controversial, generally far less effective and less widely adhered to with success. One key reason for this is that most cholesterol, typically 80-90%, within the body is created and controlled by internal production by all cells in the body (true of all animals), with typically slightly greater relative production by hepatic/liver cells. (Cell structure relies on fat membranes to separate and organize intracellular water, proteins and nucleic acids and cholesterol is one of the components of all animal cell membranes.)</p>
<p>Caldwell B Esselstyn Jr. MD has had an article published in Preventive Cardiology 2001;4: 171-177 in which he has published angiograms showing regression of atherosclerosis brought about by a very low fat vegan diet in some cases with cholesterol lowering medications.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33" title=""><span>[</span>34<span>]</span></a></sup></p>
<p>While the absolute production quantities vary with the individual, group averages for total human body content of cholesterol within the U.S. population commonly run about ~35,000 mg (assuming lean build; varies with body weight and build) and ~1,000 mg/day ongoing production. Dietary intake plays a smaller role, 200-300 mg/day being common values; for pure vegetarians, essentially 0 mg/day, but this typically does not change the situation very much because internal production increases to largely compensate for the reduced intake. For many, especially those with greater than optimal body mass and increased glucose levels, reducing carbohydrate (especially simple forms) intake, not fats or cholesterol, is often more effective for improving lipoprotein expression patterns, weight and blood glucose values. For this reason, medical authorities much less frequently promote the low dietary fat concepts than was commonly the case prior to about year 2005. However, evidence has increased that processed, particularly industrial non-enzymatic <a href="/wiki/Hydrogenation" title="Hydrogenation">hydrogenation</a> produced trans fats, as opposed to the natural <a href="/wiki/Cis" title="Cis">cis</a>-configured fats, which living cells primarily produce, is a significant health hazard.</p>
<p>Dietary supplements of Omega-3 oils, especially those from the muscle of some deep salt water living fish species, also have clinical evidence of significant protective effects as confirmed by 6 <a href="/wiki/Double_blind" title="Double blind" class="mw-redirect">double blind</a> <a href="/wiki/Placebo" title="Placebo">placebo</a> <a href="/wiki/Scientific_control" title="Scientific control">controlled</a> human clinical trials<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since October 2008" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup>.</p>
<p>There is also a variety of evidence, though less robust, that <a href="/wiki/Homocysteine" title="Homocysteine">homocysteine</a> and <a href="/wiki/Uric_acid" title="Uric acid">uric acid</a> levels, including within the normal range promote atherosclerosis and that lowering these levels is helpful, up to a point.</p>
<p>In animals <a href="/wiki/Vitamin_C" title="Vitamin C">Vitamin C</a> deficiency has been confirmed as an important role in development of <a href="/wiki/Hypercholesterolemia" title="Hypercholesterolemia">hypercholesterolemia</a> and atherosclerosis, but due to ethical reasons placebo-controlled human studies are impossible to do.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34" title=""><span>[</span>35<span>]</span></a></sup> <a href="/wiki/Vitamin_C" title="Vitamin C">Vitamin C</a> acts as an <a href="/wiki/Antioxidant" title="Antioxidant">antioxidant</a> in vessels and inhibits inflammatory process.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35" title=""><span>[</span>36<span>]</span></a></sup> It has therapeutic properties on high blood pressure and its fluctuation,<sup id="cite_ref-36" class="reference"><a href="#cite_note-36" title=""><span>[</span>37<span>]</span></a></sup><sup id="cite_ref-37" class="reference"><a href="#cite_note-37" title=""><span>[</span>38<span>]</span></a></sup> and arterial stiffness in diabetes.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38" title=""><span>[</span>39<span>]</span></a></sup> Vitamin C is also a natural regulator of cholesterol<sup id="cite_ref-39" class="reference"><a href="#cite_note-39" title=""><span>[</span>40<span>]</span></a></sup> and higher doses (over 150mg/kg daily) may confer significant protection against atherosclerosis even in the situation of elevated cholesterol levels.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40" title=""><span>[</span>41<span>]</span></a></sup><sup id="cite_ref-41" class="reference"><a href="#cite_note-41" title=""><span>[</span>42<span>]</span></a></sup></p>
<p>The scale of vitamin C benefits on cardiovascular system led several authors to the theory, that vitamin C deficiency is the primary cause of cardiovascular diseases.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42" title=""><span>[</span>43<span>]</span></a></sup> The theory was unified by twice Nobel prize winner Linus Pauling and Matthias Rath. They suggest, that clinical manifestations of cardiovascular diseases are merely overshoot of body defense mechanisms, that are involved in stabilisation of vascular wall, after it is weakened by the vitamin C deficiency and the subsequent collagen degradation. They discuss several metabolic and genetic predispositions and their pathomechanism.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43" title=""><span>[</span>44<span>]</span></a></sup></p>
<p>Trials on <a href="/wiki/Vitamin_E" title="Vitamin E">Vitamin E</a> have been done, but they have failed to find a beneficial effect, for various reasons, but for some patients at high risk for atherosclerosis there may be some benefits.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44" title=""><span>[</span>45<span>]</span></a></sup></p>
<p>Menaquinone (<a href="/wiki/Vitamin_K" title="Vitamin K">Vitamin K2</a>), but not phylloquinone (<a href="/wiki/Vitamin_K" title="Vitamin K">Vitamin K1</a>), intake is associated with reduced risk of CHD <a href="/wiki/Mortality_rate" title="Mortality rate">mortality</a>, all-cause <a href="/wiki/Mortality_rate" title="Mortality rate">mortality</a> and severe aortic calcification.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45" title=""><span>[</span>46<span>]</span></a></sup><sup id="cite_ref-46" class="reference"><a href="#cite_note-46" title=""><span>[</span>47<span>]</span></a></sup><sup id="cite_ref-47" class="reference"><a href="#cite_note-47" title=""><span>[</span>48<span>]</span></a></sup></p>
<p>It has been suggested that excess <a href="/wiki/Iron" title="Iron">iron</a> may be involved in development of atherosclerosis<sup id="cite_ref-pmid17259340_48-0" class="reference"><a href="#cite_note-pmid17259340-48" title=""><span>[</span>49<span>]</span></a></sup><sup id="cite_ref-pmid17685184_49-0" class="reference"><a href="#cite_note-pmid17685184-49" title=""><span>[</span>50<span>]</span></a></sup>, but one study found reducing body iron stores in patients with symptomatic <a href="/wiki/Peripheral_artery_occlusive_disease" title="Peripheral artery occlusive disease" class="mw-redirect">peripheral artery disease</a> through <a href="/wiki/Phlebotomy" title="Phlebotomy">phlebotomy</a> did not significantly decrease all-cause mortality or death plus nonfatal myocardial infarction and stroke.<sup id="cite_ref-pmid17299195_50-0" class="reference"><a href="#cite_note-pmid17299195-50" title=""><span>[</span>51<span>]</span></a></sup> Further studies may be warranted.</p>
<p><a name="Surgical_intervention" id="Surgical_intervention"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=19" title="Edit section: Surgical intervention">edit</a>]</span> <span class="mw-headline">Surgical intervention</span></h3>
<p>Other physical treatments, helpful in the short term, include minimally invasive <a href="/wiki/Angioplasty" title="Angioplasty">angioplasty</a> procedures that may include <a href="/wiki/Stents" title="Stents" class="mw-redirect">stents</a> to physically expand narrowed arteries<sup id="cite_ref-51" class="reference"><a href="#cite_note-51" title=""><span>[</span>52<span>]</span></a></sup> and major invasive surgery, such as <a href="/wiki/Coronary_artery_bypass_surgery" title="Coronary artery bypass surgery">bypass surgery</a>, to create additional blood supply connections that go around the more severely narrowed areas.</p>
<p><a name="Prophylaxis" id="Prophylaxis"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=20" title="Edit section: Prophylaxis">edit</a>]</span> <span class="mw-headline">Prophylaxis</span></h3>
<p>Patients at risk for atherosclerosis-related diseases are increasingly being treated <a href="/wiki/Prophylaxis" title="Prophylaxis">prophylactically</a> with low-dose <a href="/wiki/Aspirin" title="Aspirin">aspirin</a> and a <a href="/wiki/Statin" title="Statin">statin</a>. The high incidence of cardiovascular disease led Wald and Law<sup id="cite_ref-Polypill_52-0" class="reference"><a href="#cite_note-Polypill-52" title=""><span>[</span>53<span>]</span></a></sup> to propose a <i><a href="/wiki/Polypill" title="Polypill">Polypill</a></i>, a once-daily pill containing these two types of drugs in addition to an <a href="/wiki/ACE_inhibitor" title="ACE inhibitor">ACE inhibitor</a>, <a href="/wiki/Diuretic" title="Diuretic">diuretic</a>, <a href="/wiki/Beta_blocker" title="Beta blocker">beta blocker</a>, and <a href="/wiki/Folic_acid" title="Folic acid">folic acid</a>. They maintain that high uptake by the general population by such a <i>Polypill</i> would reduce cardiovascular mortality by 80%. It must be emphasized however that this is purely theoretical, as the Polypill has never been tested in a clinical trial.</p>
<p>Medical treatments often focus predominantly on the symptoms. However, over time, the treatments which focus on decreasing the underlying atherosclerosis processes, as opposed to simply treating the symptoms resulting from the atherosclerosis, have been shown by clinical trials to be more effective.</p>
<p>In summary, the key to the more effective approaches has been better understanding of the widespread and insidious nature of the disease and to combine multiple different treatment strategies, not rely on just one or a few approaches. In addition, for those approaches, such as lipoprotein transport behaviors, which have been shown to produce the most success, adopting more aggressive combination treatment strategies has generally produced better results, both before and especially after people are symptomatic. However, treating asymptomatic people remains controversial in the medical community.</p>
<p>Because many blood thinners, particularly salicylates such as warfarin and aspirin thin the blood by interfering with Vitamin K, there is recent evidence that blood thinners which work by this mechanism, can actually worsen arterial calcification in the long term even though they thin the blood in the short term.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53" title=""><span>[</span>54<span>]</span></a></sup><sup id="cite_ref-54" class="reference"><a href="#cite_note-54" title=""><span>[</span>55<span>]</span></a></sup> <a href="http://lpi.oregonstate.edu/infocenter/vitamins/vitaminK/" class="external autonumber" title="http://lpi.oregonstate.edu/infocenter/vitamins/vitaminK/" rel="nofollow">[2]</a><a href="http://glycodocs.org/index.php?option=com_content&amp;task=view&amp;id=100&amp;Itemid=52" class="external autonumber" title="http://glycodocs.org/index.php?option=com_content&amp;task=view&amp;id=100&amp;Itemid=52" rel="nofollow">[3]</a></p>
<p><a name="Recent_research" id="Recent_research"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=21" title="Edit section: Recent research">edit</a>]</span> <span class="mw-headline">Recent research</span></h2>
<p>An indication of the role of HDL on atherosclerosis has been with the rare Apo-A1 Milano human genetic variant of this HDL protein. A small short-term trial using bacterial synthetized human <a href="/wiki/ApoA-1_Milano" title="ApoA-1 Milano">Apo-A1 Milano</a> HDL in people with unstable angina produced fairly dramatic reduction in measured coronary plaque volume in only 6 weeks vs. the usual increase in plaque volume in those randomized to placebo. The trial was published in JAMA in early 2006. Ongoing work starting in the 1990s may lead to human clinical trials—probably by about 2008. These may use synthesized Apo-A1 Milano HDL directly. Or they may use gene-transfer methods to pass the ability to synthesize the Apo-A1 Milano HDLipoprotein.</p>
<p>Methods to increase <a href="/wiki/High-density_lipoprotein" title="High-density lipoprotein">high-density lipoprotein</a> (HDL) particle concentrations, which in some animal studies largely reverses and remove atheromas, are being developed and researched.</p>
<p><a href="/wiki/Niacin" title="Niacin">Niacin</a> has HDL raising effects (by 10 - 30%) and showed clinical trial benefit in the Coronary Drug Project and is commonly used in combination with other lipoprotein agents to improve efficacy of changing lipoprotein for the better. However most individuals have nuisance symptoms with short term flushing reactions, especially initially, and so working with a physician with a history of successful experience with niacin implementation, careful selection of brand, dosing strategy, etc. are usually critical to success.</p>
<p>However, increasing HDL by any means is not necessarily helpful. For example, the drug <a href="/wiki/Torcetrapib" title="Torcetrapib">torcetrapib</a> is the most effective agent currently known for raising HDL (by up to 60%). However, in clinical trials it also raised deaths by 60%. All studies regarding this drug were halted in December 2006.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55" title=""><span>[</span>56<span>]</span></a></sup></p>
<p>The ERASE trial is a newer trial of an HDL booster which has shown promise.<sup id="cite_ref-Hughes_56-0" class="reference"><a href="#cite_note-Hughes-56" title=""><span>[</span>57<span>]</span></a></sup></p>
<p>The ASTEROID trial used a high-dose of <a href="/wiki/Rosuvastatin" title="Rosuvastatin">rosuvastatin</a>—the statin with typically the most potent dose/response correlation track record (both for LDLipoproteins and HDLipoproteins.) It found plaque (intima + media volume) reduction.<sup id="cite_ref-Nissen_7-3" class="reference"><a href="#cite_note-Nissen-7" title=""><span>[</span>8<span>]</span></a></sup> Several additional rosuvastatin treatment/placebo trials for evaluating other clinical outcomes are in progress.</p>
<p>The actions of macrophages drive atherosclerotic plaque progression. <i>Immunomodulation of atherosclerosis</i> is the term for techniques which modulate immune system function in order to suppress this macrophage action.<sup id="cite_ref-Nilsson_57-0" class="reference"><a href="#cite_note-Nilsson-57" title=""><span>[</span>58<span>]</span></a></sup> Immunomodulation has been pursued with considerable success in both mice and rabbits since about 2002. Plans for human trials, hoped for by about 2008, are in progress.</p>
<p>Research on genetic expression and control mechanisms is progressing. Topics include</p>
<ul>
<li><a href="/wiki/Peroxisome_proliferator-activated_receptors" title="Peroxisome proliferator-activated receptors" class="mw-redirect">PPAR</a>, known to be important in blood sugar and variants of lipoprotein production and function;</li>
<li>The multiple variants of the proteins that form the lipoprotein transport particles.</li>
</ul>
<p>Some controversial research has suggested a link between atherosclerosis and the presence of several different <a href="/wiki/Nanobacterium" title="Nanobacterium">nanobacteria</a> in the arteries, e.g., <a href="/wiki/Chlamydophila_pneumoniae" title="Chlamydophila pneumoniae">Chlamydophila pneumoniae</a>, though trials of current antibiotic treatments known to be usually effective in suppressing growth or killing these bacteria have not been successful in improving outcomes.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58" title=""><span>[</span>59<span>]</span></a></sup></p>
<p>The immunomodulation approaches mentioned above, because they deal with innate responses of the host to promote atherosclerosis, have far greater prospects for success.</p>
<p>The <a href="http://www.nhlbi.nih.gov/" class="external text" title="http://www.nhlbi.nih.gov/" rel="nofollow">National Heart, Lung, and Blood Institute (NHLBI)</a> and <a href="http://nccam.nih.gov/" class="external text" title="http://nccam.nih.gov/" rel="nofollow">National Center for Complementary and Alternative Medicine (NCCAM)</a> sponsored <a href="http://www.clinicaltrials.gov/ct/show/NCT00044213?order=2" class="external text" title="http://www.clinicaltrials.gov/ct/show/NCT00044213?order=2" rel="nofollow">The Trial to Assess Chelation Therapy (TACT)</a>. The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease. EDTA chelation therapy involves repeated administrations of a synthetic amino acid to reduce atherosclerotic plaque and other mineral deposits throughout the cardiovascular system. The results of TACT will provide either a significant positive result or an informative null result upon which rational clinical decision-making and health policy can be based.</p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=22" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="/wiki/Angiogram" title="Angiogram" class="mw-redirect">Angiogram</a></li>
<li><a href="/wiki/Arterial_stiffness" title="Arterial stiffness">Arterial stiffness</a></li>
<li><a href="/wiki/Atheroma" title="Atheroma">Atheroma</a></li>
<li><a href="/wiki/Chelation_therapy" title="Chelation therapy">Chelation therapy</a></li>
<li><a href="/wiki/Coronary_circulation" title="Coronary circulation">Coronary circulation</a></li>
<li><a href="/wiki/Coronary_catheterization" title="Coronary catheterization">Coronary catheterization</a></li>
<li><a href="/wiki/Fatty_streaks" title="Fatty streaks" class="mw-redirect">Fatty streaks</a></li>
<li><a href="/wiki/Monckeberg%27s_arteriosclerosis" title="Monckeberg's arteriosclerosis">Monckeberg's arteriosclerosis</a></li>
<li><a href="/wiki/Intravascular_ultrasound" title="Intravascular ultrasound">Intravascular ultrasound</a></li>
</ul>
<p><a name="Footnotes" id="Footnotes"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=23" title="Edit section: Footnotes">edit</a>]</span> <span class="mw-headline">Footnotes</span></h2>
<div class="references-small references-column-count references-column-count-2" style="-moz-column-count:2; column-count:2;">
<ol class="references">
<li id="cite_note-0"><b><a href="#cite_ref-0" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFMatonRoshan_L._Jean_Hopkins.2C_Charles_William_McLaughlin.2C_Susan_Johnson.2C_Maryanna_Quon_Warner.2C_David_LaHart.2C_Jill_D._Wright1993">Maton, Anthea; Roshan L. Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D. Wright (1993). <i>Human Biology and Health</i>. Englewood Cliffs, New Jersey, USA: Prentice Hall. <a href="/wiki/Special:BookSources/0139811761" class="internal">ISBN 0-13-981176-1</a>. <a href="/wiki/Online_Computer_Library_Center" title="Online Computer Library Center">OCLC</a> <a href="http://worldcat.org/oclc/32308337" class="external text" title="http://worldcat.org/oclc/32308337" rel="nofollow">32308337</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Human+Biology+and+Health&amp;rft.aulast=Maton&amp;rft.aufirst=Anthea&amp;rft.au=Maton%2C+Anthea&amp;rft.au=Roshan+L.+Jean+Hopkins%2C+Charles+William+McLaughlin%2C+Susan+Johnson%2C+Maryanna+Quon+Warner%2C+David+LaHart%2C+Jill+D.+Wright&amp;rft.date=1993&amp;rft.place=Englewood+Cliffs%2C+New+Jersey%2C+USA&amp;rft.pub=Prentice+Hall&amp;rft_id=info:oclcnum/32308337&amp;rft.isbn=0-13-981176-1&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-1"><b><a href="#cite_ref-1" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFFabricant_CG.2C_Fabricant_J1999">Fabricant CG, Fabricant J (1999). "Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens". <i>Am Heart J</i> <b>138</b> (5 Pt 2): S465–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0002-8703%2899%2970276-0" class="external text" title="http://dx.doi.org/10.1016%2FS0002-8703%2899%2970276-0" rel="nofollow">10.1016/S0002-8703(99)70276-0</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10539849" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10539849">PMID 10539849</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Atherosclerosis+induced+by+infection+with+Marek%27s+disease+herpesvirus+in+chickens&amp;rft.jtitle=Am+Heart+J&amp;rft.aulast=Fabricant+CG%2C+Fabricant+J&amp;rft.au=Fabricant+CG%2C+Fabricant+J&amp;rft.date=1999&amp;rft.volume=138&amp;rft.issue=5+Pt+2&amp;rft.pages=S465%E2%80%938&amp;rft_id=info:doi/10.1016%2FS0002-8703%2899%2970276-0&amp;rft_id=info:pmid/10539849&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-2"><b><a href="#cite_ref-2" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHsu_HY.2C_Nicholson_AC.2C_Pomerantz_KB.2C_Kaner_RJ.2C_Hajjar_DP1995">Hsu HY, Nicholson AC, Pomerantz KB, Kaner RJ, Hajjar DP (August 1995). "<a href="http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=7642651" class="external text" title="http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=7642651" rel="nofollow">Altered cholesterol trafficking in herpesvirus-infected arterial cells. Evidence for viral protein kinase-mediated cholesterol accumulation</a>". <i>J Biol Chem</i> <b>270</b> (33): 19630–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1074%2Fjbc.270.33.19630" class="external text" title="http://dx.doi.org/10.1074%2Fjbc.270.33.19630" rel="nofollow">10.1074/jbc.270.33.19630</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7642651" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7642651">PMID 7642651</a><span class="printonly">. <a href="http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=7642651" class="external free" title="http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=7642651" rel="nofollow">http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=7642651</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Altered+cholesterol+trafficking+in+herpesvirus-infected+arterial+cells.+Evidence+for+viral+protein+kinase-mediated+cholesterol+accumulation&amp;rft.jtitle=J+Biol+Chem&amp;rft.aulast=Hsu+HY%2C+Nicholson+AC%2C+Pomerantz+KB%2C+Kaner+RJ%2C+Hajjar+DP&amp;rft.au=Hsu+HY%2C+Nicholson+AC%2C+Pomerantz+KB%2C+Kaner+RJ%2C+Hajjar+DP&amp;rft.date=August+1995&amp;rft.volume=270&amp;rft.issue=33&amp;rft.pages=19630%E2%80%937&amp;rft_id=info:doi/10.1074%2Fjbc.270.33.19630&amp;rft_id=info:pmid/7642651&amp;rft_id=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D7642651&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-3"><b><a href="#cite_ref-3" title="">^</a></b> Summary of <a href="http://www.itamar-medical.com/Product.asp?pid=3983&amp;ppid=3005" class="external text" title="http://www.itamar-medical.com/Product.asp?pid=3983&amp;ppid=3005" rel="nofollow">subclinical atherosclerosis</a> at Itamar Medical</li>
<li id="cite_note-pmid11390341-4"><b><a href="#cite_ref-pmid11390341_4-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTuzcu_EM.2C_Kapadia_SR.2C_Tutar_E.2C_.27.27et_al.27.272001">Tuzcu EM, Kapadia SR, Tutar E, <i>et al</i> (2001-06-05). "<a href="http://circ.ahajournals.org/cgi/reprint/103/22/2705" class="external text" title="http://circ.ahajournals.org/cgi/reprint/103/22/2705" rel="nofollow">High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound</a>". <i>Circulation</i> <b>103</b> (22): 2705–10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11390341" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11390341">PMID 11390341</a><span class="printonly">. <a href="http://circ.ahajournals.org/cgi/reprint/103/22/2705" class="external free" title="http://circ.ahajournals.org/cgi/reprint/103/22/2705" rel="nofollow">http://circ.ahajournals.org/cgi/reprint/103/22/2705</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=High+prevalence+of+coronary+atherosclerosis+in+asymptomatic+teenagers+and+young+adults%3A+evidence+from+intravascular+ultrasound&amp;rft.jtitle=Circulation&amp;rft.aulast=Tuzcu+EM%2C+Kapadia+SR%2C+Tutar+E%2C+%27%27et+al%27%27&amp;rft.au=Tuzcu+EM%2C+Kapadia+SR%2C+Tutar+E%2C+%27%27et+al%27%27&amp;rft.date=2001-06-05&amp;rft.volume=103&amp;rft.issue=22&amp;rft.pages=2705%E2%80%9310&amp;rft_id=info:pmid/11390341&amp;rft_id=http%3A%2F%2Fcirc.ahajournals.org%2Fcgi%2Freprint%2F103%2F22%2F2705&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-5"><b><a href="#cite_ref-5" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFMichael_C._Fishbein.2C_M.D.">Michael C. Fishbein, M.D.. <a href="http://www.medicinenet.com/heart_attack_pathology_photo_essay/page2.htm" class="external text" title="http://www.medicinenet.com/heart_attack_pathology_photo_essay/page2.htm" rel="nofollow">"Heart Attack Photo Illustration Essay on MedicineNet.com"</a><span class="printonly">. <a href="http://www.medicinenet.com/heart_attack_pathology_photo_essay/page2.htm" class="external free" title="http://www.medicinenet.com/heart_attack_pathology_photo_essay/page2.htm" rel="nofollow">http://www.medicinenet.com/heart_attack_pathology_photo_essay/page2.htm</a></span><span class="reference-accessdate">. Retrieved on 2007-11-02</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Heart+Attack+Photo+Illustration+Essay+on+MedicineNet.com&amp;rft.atitle=&amp;rft.aulast=Michael+C.+Fishbein%2C+M.D.&amp;rft.au=Michael+C.+Fishbein%2C+M.D.&amp;rft_id=http%3A%2F%2Fwww.medicinenet.com%2Fheart_attack_pathology_photo_essay%2Fpage2.htm&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Glagov-6">^ <a href="#cite_ref-Glagov_6-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Glagov_6-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFGlagov_S.2C_Weisenberg_E.2C_Zarins_CK.2C_Stankunavicius_R.2C_Kolettis_GJ1987">Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ (May 1987). "Compensatory enlargement of human atherosclerotic coronary arteries". <i>N. Engl. J. Med.</i> <b>316</b> (22): 1371–5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3574413" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/3574413">PMID 3574413</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Compensatory+enlargement+of+human+atherosclerotic+coronary+arteries&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.aulast=Glagov+S%2C+Weisenberg+E%2C+Zarins+CK%2C+Stankunavicius+R%2C+Kolettis+GJ&amp;rft.au=Glagov+S%2C+Weisenberg+E%2C+Zarins+CK%2C+Stankunavicius+R%2C+Kolettis+GJ&amp;rft.date=May+1987&amp;rft.volume=316&amp;rft.issue=22&amp;rft.pages=1371%E2%80%935&amp;rft_id=info:pmid/3574413&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Nissen-7">^ <a href="#cite_ref-Nissen_7-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nissen_7-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Nissen_7-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Nissen_7-3" title=""><sup><i><b>d</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFNissen">Nissen. "<a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external text" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">"Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis–The ASTEROID Trial"</a>". <i>JAMA</i><span class="printonly">. <a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external free" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=%22Effect+of+Very+High-Intensity+Statin+Therapy+on+Regression+of+Coronary+Atherosclerosis%26ndash%3BThe+ASTEROID+Trial%22&amp;rft.jtitle=JAMA&amp;rft.aulast=Nissen&amp;rft.au=Nissen&amp;rft_id=http%3A%2F%2Fjama.ama-assn.org%2Fcgi%2Freprint%2Fjama%3B295%2F13%2F1556.pdf%3Fijkey%3DMd42dlk7z9TzyL8%26keytype%3Dfinite&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-MaseriFuster-8"><b><a href="#cite_ref-MaseriFuster_8-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMaseri_A.2C_Fuster_V2003">Maseri A, Fuster V (2003). "Is there a vulnerable plaque?". <i>Circulation</i> <b>107</b> (16): 2068–71. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1161%2F01.CIR.0000070585.48035.D1" class="external text" title="http://dx.doi.org/10.1161%2F01.CIR.0000070585.48035.D1" rel="nofollow">10.1161/01.CIR.0000070585.48035.D1</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12719286" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12719286">PMID 12719286</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Is+there+a+vulnerable+plaque%3F&amp;rft.jtitle=Circulation&amp;rft.aulast=Maseri+A%2C+Fuster+V&amp;rft.au=Maseri+A%2C+Fuster+V&amp;rft.date=2003&amp;rft.volume=107&amp;rft.issue=16&amp;rft.pages=2068%E2%80%9371&amp;rft_id=info:doi/10.1161%2F01.CIR.0000070585.48035.D1&amp;rft_id=info:pmid/12719286&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Blankenhorn-9">^ <a href="#cite_ref-Blankenhorn_9-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Blankenhorn_9-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFBlankenhorn_DH.2C_Hodis_HN1993">Blankenhorn DH, Hodis HN (August 1993). "<a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1022223" class="external text" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1022223" rel="nofollow">Atherosclerosis--reversal with therapy</a>". <i>The Western journal of medicine</i> <b>159</b> (2): 172–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8212682" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8212682">PMID 8212682</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Atherosclerosis--reversal+with+therapy&amp;rft.jtitle=The+Western+journal+of+medicine&amp;rft.aulast=Blankenhorn+DH%2C+Hodis+HN&amp;rft.au=Blankenhorn+DH%2C+Hodis+HN&amp;rft.date=August+1993&amp;rft.volume=159&amp;rft.issue=2&amp;rft.pages=172%E2%80%939&amp;rft_id=info:pmid/8212682&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Kumar345-10">^ <a href="#cite_ref-Kumar345_10-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Kumar345_10-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Kumar345_10-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Kumar345_10-3" title=""><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Kumar345_10-4" title=""><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Kumar345_10-5" title=""><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Kumar345_10-6" title=""><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Kumar345_10-7" title=""><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Kumar345_10-8" title=""><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Kumar345_10-9" title=""><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Kumar345_10-10" title=""><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Kumar345_10-11" title=""><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Kumar345_10-12" title=""><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Kumar345_10-13" title=""><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Kumar345_10-14" title=""><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Kumar345_10-15" title=""><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Kumar345_10-16" title=""><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Kumar345_10-17" title=""><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Kumar345_10-18" title=""><sup><i><b>s</b></i></sup></a> <cite style="font-style:normal" class="book" id="CITEREFMitchell.2C_Richard_Sheppard.3B_Kumar.2C_Vinay.3B_Abbas.2C_Abul_K..3B_Fausto.2C_Nelson2007">Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007). <i>Robbins Basic Pathology: With STUDENT CONSULT Online Access</i>. Philadelphia: Saunders. pp.&#160;345. <a href="/wiki/Special:BookSources/1416029737" class="internal">ISBN 1-4160-2973-7</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Robbins+Basic+Pathology%3A+With+STUDENT+CONSULT+Online+Access&amp;rft.aulast=Mitchell%2C+Richard+Sheppard%3B+Kumar%2C+Vinay%3B+Abbas%2C+Abul+K.%3B+Fausto%2C+Nelson&amp;rft.au=Mitchell%2C+Richard+Sheppard%3B+Kumar%2C+Vinay%3B+Abbas%2C+Abul+K.%3B+Fausto%2C+Nelson&amp;rft.date=2007&amp;rft.pages=pp.%26nbsp%3B345&amp;rft.place=Philadelphia&amp;rft.pub=Saunders&amp;rft.isbn=1-4160-2973-7&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span> 8th edition.</li>
<li id="cite_note-Bhatt-11"><b><a href="#cite_ref-Bhatt_11-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBhatt_DL.2C_Topol_EJ2002">Bhatt DL, Topol EJ (July 2002). "<a href="http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136" class="external text" title="http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136" rel="nofollow">Need to test the arterial inflammation hypothesis</a>". <i>Circulation</i> <b>106</b> (1): 136–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1161%2F01.CIR.0000021112.29409.A2" class="external text" title="http://dx.doi.org/10.1161%2F01.CIR.0000021112.29409.A2" rel="nofollow">10.1161/01.CIR.0000021112.29409.A2</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12093783" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12093783">PMID 12093783</a><span class="printonly">. <a href="http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136" class="external free" title="http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136" rel="nofollow">http://circ.ahajournals.org/cgi/content/full/circulationaha;106/1/136</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Need+to+test+the+arterial+inflammation+hypothesis&amp;rft.jtitle=Circulation&amp;rft.aulast=Bhatt+DL%2C+Topol+EJ&amp;rft.au=Bhatt+DL%2C+Topol+EJ&amp;rft.date=July+2002&amp;rft.volume=106&amp;rft.issue=1&amp;rft.pages=136%E2%80%9340&amp;rft_id=info:doi/10.1161%2F01.CIR.0000021112.29409.A2&amp;rft_id=info:pmid/12093783&amp;rft_id=http%3A%2F%2Fcirc.ahajournals.org%2Fcgi%2Fcontent%2Ffull%2Fcirculationaha%3B106%2F1%2F136&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Hyperinsulinaemia-12"><b><a href="#cite_ref-Hyperinsulinaemia_12-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGriffin_M.2C_Frazer_A.2C_Johnson_A.2C_Collins_P.2C_Owens_D.2C_Tomkin_GH1998">Griffin M, Frazer A, Johnson A, Collins P, Owens D, Tomkin GH (1998). "Cellular cholesterol synthesis--the relationship to post-prandial glucose and insulin following weight loss". <i>Atherosclerosis.</i> <b>138</b> (2): 313–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0021-9150%2898%2900036-7" class="external text" title="http://dx.doi.org/10.1016%2FS0021-9150%2898%2900036-7" rel="nofollow">10.1016/S0021-9150(98)00036-7</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9690914" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9690914">PMID 9690914</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cellular+cholesterol+synthesis--the+relationship+to+post-prandial+glucose+and+insulin+following+weight+loss&amp;rft.jtitle=Atherosclerosis.&amp;rft.aulast=Griffin+M%2C+Frazer+A%2C+Johnson+A%2C+Collins+P%2C+Owens+D%2C+Tomkin+GH&amp;rft.au=Griffin+M%2C+Frazer+A%2C+Johnson+A%2C+Collins+P%2C+Owens+D%2C+Tomkin+GH&amp;rft.date=1998&amp;rft.volume=138&amp;rft.issue=2&amp;rft.pages=313%E2%80%938&amp;rft_id=info:doi/10.1016%2FS0021-9150%2898%2900036-7&amp;rft_id=info:pmid/9690914&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-13"><b><a href="#cite_ref-13" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKing.2C_Cr.3B_Knutson.2C_Kl.3B_Rathouz.2C_Pj.3B_Sidney.2C_S.3B_Liu.2C_K.3B_Lauderdale.2C_Ds2008">King, Cr; Knutson, Kl; Rathouz, Pj; Sidney, S; Liu, K; Lauderdale, Ds (Dec 2008). "Short sleep duration and incident coronary artery calcification.". <i>JAMA&#160;: the journal of the American Medical Association</i> <b>300</b> (24): 2859–66. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.2008.867" class="external text" title="http://dx.doi.org/10.1001%2Fjama.2008.867" rel="nofollow">10.1001/jama.2008.867</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19109114" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/19109114">PMID 19109114</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Short+sleep+duration+and+incident+coronary+artery+calcification.&amp;rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&amp;rft.aulast=King%2C+Cr%3B+Knutson%2C+Kl%3B+Rathouz%2C+Pj%3B+Sidney%2C+S%3B+Liu%2C+K%3B+Lauderdale%2C+Ds&amp;rft.au=King%2C+Cr%3B+Knutson%2C+Kl%3B+Rathouz%2C+Pj%3B+Sidney%2C+S%3B+Liu%2C+K%3B+Lauderdale%2C+Ds&amp;rft.date=Dec+2008&amp;rft.volume=300&amp;rft.issue=24&amp;rft.pages=2859%E2%80%9366&amp;rft_id=info:doi/10.1001%2Fjama.2008.867&amp;rft_id=info:pmid/19109114&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-titleFood_Pyramids:_Nutrition_Source.2C_Harvard_School_of_Public_Health-14"><b><a href="#cite_ref-titleFood_Pyramids:_Nutrition_Source.2C_Harvard_School_of_Public_Health_14-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.hsph.harvard.edu/nutritionsource/pyramids.html" class="external text" title="http://www.hsph.harvard.edu/nutritionsource/pyramids.html" rel="nofollow">"Food Pyramids: Nutrition Source, Harvard School of Public Health"</a><span class="printonly">. <a href="http://www.hsph.harvard.edu/nutritionsource/pyramids.html" class="external free" title="http://www.hsph.harvard.edu/nutritionsource/pyramids.html" rel="nofollow">http://www.hsph.harvard.edu/nutritionsource/pyramids.html</a></span><span class="reference-accessdate">. Retrieved on 2007-11-25</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Food+Pyramids%3A+Nutrition+Source%2C+Harvard+School+of+Public+Health&amp;rft.atitle=&amp;rft_id=http%3A%2F%2Fwww.hsph.harvard.edu%2Fnutritionsource%2Fpyramids.html&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Taubes-15"><b><a href="#cite_ref-Taubes_15-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTaubes_G2001">Taubes G (March 2001). "<a href="http://www.sciencemag.org/cgi/pmidlookup?view=long&amp;pmid=11286266" class="external text" title="http://www.sciencemag.org/cgi/pmidlookup?view=long&amp;pmid=11286266" rel="nofollow">Nutrition. The soft science of dietary fat</a>". <i>Science (New York, N.Y.)</i> <b>291</b> (5513): 2536–45. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1126%2Fscience.291.5513.2536" class="external text" title="http://dx.doi.org/10.1126%2Fscience.291.5513.2536" rel="nofollow">10.1126/science.291.5513.2536</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11286266" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11286266">PMID 11286266</a><span class="printonly">. <a href="http://www.sciencemag.org/cgi/pmidlookup?view=long&amp;pmid=11286266" class="external free" title="http://www.sciencemag.org/cgi/pmidlookup?view=long&amp;pmid=11286266" rel="nofollow">http://www.sciencemag.org/cgi/pmidlookup?view=long&amp;pmid=11286266</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Nutrition.+The+soft+science+of+dietary+fat&amp;rft.jtitle=Science+%28New+York%2C+N.Y.%29&amp;rft.aulast=Taubes+G&amp;rft.au=Taubes+G&amp;rft.date=March+2001&amp;rft.volume=291&amp;rft.issue=5513&amp;rft.pages=2536%E2%80%9345&amp;rft_id=info:doi/10.1126%2Fscience.291.5513.2536&amp;rft_id=info:pmid/11286266&amp;rft_id=http%3A%2F%2Fwww.sciencemag.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D11286266&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-SongJH-16"><b><a href="#cite_ref-SongJH_16-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSong_JH.2C_Fujimoto_K.2C_Miyazawa_T2000">Song JH, Fujimoto K, Miyazawa T (2000). "Polyunsaturated (n-3) fatty acids susceptible to peroxidation are increased in plasma and tissue lipids of rats fed docosahexaenoic acid-containing oils". <i>J. Nutr.</i> <b>130</b> (12): 3028–33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11110863" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11110863">PMID 11110863</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Polyunsaturated+%28n-3%29+fatty+acids+susceptible+to+peroxidation+are+increased+in+plasma+and+tissue+lipids+of+rats+fed+docosahexaenoic+acid-containing+oils&amp;rft.jtitle=J.+Nutr.&amp;rft.aulast=Song+JH%2C+Fujimoto+K%2C+Miyazawa+T&amp;rft.au=Song+JH%2C+Fujimoto+K%2C+Miyazawa+T&amp;rft.date=2000&amp;rft.volume=130&amp;rft.issue=12&amp;rft.pages=3028%E2%80%9333&amp;rft_id=info:pmid/11110863&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-YapSC-17"><b><a href="#cite_ref-YapSC_17-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFYap_SC.2C_Choo_YM.2C_Hew_NF.2C_.27.27et_al.27.271995">Yap SC, Choo YM, Hew NF, <i>et al</i> (1995). "Oxidative susceptibility of low density lipoprotein from rabbits fed atherogenic diets containing coconut, palm, or soybean oils". <i>Lipids</i> <b>30</b> (12): 1145–50. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1007%2FBF02536616" class="external text" title="http://dx.doi.org/10.1007%2FBF02536616" rel="nofollow">10.1007/BF02536616</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8614305" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8614305">PMID 8614305</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Oxidative+susceptibility+of+low+density+lipoprotein+from+rabbits+fed+atherogenic+diets+containing+coconut%2C+palm%2C+or+soybean+oils&amp;rft.jtitle=Lipids&amp;rft.aulast=Yap+SC%2C+Choo+YM%2C+Hew+NF%2C+%27%27et+al%27%27&amp;rft.au=Yap+SC%2C+Choo+YM%2C+Hew+NF%2C+%27%27et+al%27%27&amp;rft.date=1995&amp;rft.volume=30&amp;rft.issue=12&amp;rft.pages=1145%E2%80%9350&amp;rft_id=info:doi/10.1007%2FBF02536616&amp;rft_id=info:pmid/8614305&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Greco-18"><b><a href="#cite_ref-Greco_18-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGreco_AV.2C_Mingrone_G1990">Greco AV, Mingrone G (1990). "Serum and biliary lipid pattern in rabbits feeding a diet enriched with unsaturated fatty acids". <i>Exp Pathol</i> <b>40</b> (1): 19–33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2279534" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2279534">PMID 2279534</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serum+and+biliary+lipid+pattern+in+rabbits+feeding+a+diet+enriched+with+unsaturated+fatty+acids&amp;rft.jtitle=Exp+Pathol&amp;rft.aulast=Greco+AV%2C+Mingrone+G&amp;rft.au=Greco+AV%2C+Mingrone+G&amp;rft.date=1990&amp;rft.volume=40&amp;rft.issue=1&amp;rft.pages=19%E2%80%9333&amp;rft_id=info:pmid/2279534&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid16249011-19"><b><a href="#cite_ref-pmid16249011_19-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMattes_RD2005">Mattes RD (2005). "<a href="http://linkinghub.elsevier.com/retrieve/pii/S0031-9384(05)00397-5" class="external text" title="http://linkinghub.elsevier.com/retrieve/pii/S0031-9384(05)00397-5" rel="nofollow">Fat taste and lipid metabolism in humans</a>". <i>Physiol. Behav.</i> <b>86</b> (5): 691–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.physbeh.2005.08.058" class="external text" title="http://dx.doi.org/10.1016%2Fj.physbeh.2005.08.058" rel="nofollow">10.1016/j.physbeh.2005.08.058</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16249011" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16249011">PMID 16249011</a><span class="printonly">. <a href="http://linkinghub.elsevier.com/retrieve/pii/S0031-9384(05)00397-5" class="external free" title="http://linkinghub.elsevier.com/retrieve/pii/S0031-9384(05)00397-5" rel="nofollow">http://linkinghub.elsevier.com/retrieve/pii/S0031-9384(05)00397-5</a></span>.  "The rancid odor of an oxidized fat is readily detectable".</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Fat+taste+and+lipid+metabolism+in+humans&amp;rft.jtitle=Physiol.+Behav.&amp;rft.aulast=Mattes+RD&amp;rft.au=Mattes+RD&amp;rft.date=2005&amp;rft.volume=86&amp;rft.issue=5&amp;rft.pages=691%E2%80%937&amp;rft_id=info:doi/10.1016%2Fj.physbeh.2005.08.058&amp;rft_id=info:pmid/16249011&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0031-9384%2805%2900397-5&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid12589185-20"><b><a href="#cite_ref-pmid12589185_20-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDobarganes_C.2C_M.C3.A1rquez-Ruiz_G2003">Dobarganes C, Márquez-Ruiz G (2003). "Oxidized fats in foods". <i>Curr Opin Clin Nutr Metab Care</i> <b>6</b> (2): 157–63. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:10.1097/01.mco.0000058585.27240.ee (inactive 2008-06-27). <a href="http://www.ncbi.nlm.nih.gov/pubmed/12589185" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12589185">PMID 12589185</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Oxidized+fats+in+foods&amp;rft.jtitle=Curr+Opin+Clin+Nutr+Metab+Care&amp;rft.aulast=Dobarganes+C%2C+M%C3%A1rquez-Ruiz+G&amp;rft.au=Dobarganes+C%2C+M%C3%A1rquez-Ruiz+G&amp;rft.date=2003&amp;rft.volume=6&amp;rft.issue=2&amp;rft.pages=157%E2%80%9363&amp;rft_id=info:doi/10.1097%2F01.mco.0000058585.27240.ee&amp;rft_id=info:pmid/12589185&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-21"><b><a href="#cite_ref-21" title="">^</a></b> <a href="http://www.udoerasmus.com/articles/udo/hbaco.htm" class="external text" title="http://www.udoerasmus.com/articles/udo/hbaco.htm" rel="nofollow">How Bad Are Cooking Oils?</a> by <a href="/w/index.php?title=Udo_Erasmus&amp;action=edit&amp;redlink=1" class="new" title="Udo Erasmus (page does not exist)">Udo Erasmus</a>, PhD</li>
<li id="cite_note-die-22"><b><a href="#cite_ref-die_22-0" title="">^</a></b> <a href="http://www.marininstitute.org/alcohol_policy/french_drinking.htm" class="external text" title="http://www.marininstitute.org/alcohol_policy/french_drinking.htm" rel="nofollow">"Drink Like the French, Die Like the French"</a></li>
<li id="cite_note-23"><b><a href="#cite_ref-23" title="">^</a></b> <a href="http://herbalwhirled.blogspot.com/2006/11/pasteurized-homogenized-milk-and-your.html" class="external free" title="http://herbalwhirled.blogspot.com/2006/11/pasteurized-homogenized-milk-and-your.html" rel="nofollow">http://herbalwhirled.blogspot.com/2006/11/pasteurized-homogenized-milk-and-your.html</a></li>
<li id="cite_note-pmid12479764-24"><b><a href="#cite_ref-pmid12479764_24-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFThe_Allhat_Officers_And_Coordinators_For_The_Allhat_Collaborative_Research_Group.2C2002">The Allhat Officers And Coordinators For The Allhat Collaborative Research Group, (2002). "Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)". <i>JAMA</i> <b>288</b> (23): 2998–3007. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:10.1001/jama.288.23.2998 (inactive 2009-04-03). <a href="http://www.ncbi.nlm.nih.gov/pubmed/12479764" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12479764">PMID 12479764</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Major+outcomes+in+moderately+hypercholesterolemic%2C+hypertensive+patients+randomized+to+pravastatin+vs+usual+care%3A+The+Antihypertensive+and+Lipid-Lowering+Treatment+to+Prevent+Heart+Attack+Trial+%28ALLHAT-LLT%29&amp;rft.jtitle=JAMA&amp;rft.aulast=The+Allhat+Officers+And+Coordinators+For+The+Allhat+Collaborative+Research+Group%2C&amp;rft.au=The+Allhat+Officers+And+Coordinators+For+The+Allhat+Collaborative+Research+Group%2C&amp;rft.date=2002&amp;rft.volume=288&amp;rft.issue=23&amp;rft.pages=2998%E2%80%933007&amp;rft_id=info:doi/10.1001%2Fjama.288.23.2998&amp;rft_id=info:pmid/12479764&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-25"><b><a href="#cite_ref-25" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFVos_E.2C_Rose_CP2005">Vos E, Rose CP (November 2005). "<a href="http://www.cmaj.ca/cgi/content/full/173/10/1207-a" class="external text" title="http://www.cmaj.ca/cgi/content/full/173/10/1207-a" rel="nofollow">Questioning the benefits of statins</a>". <i>CMAJ</i> <b>173</b> (10): 1207; author reply 1210. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1503%2Fcmaj.1050120" class="external text" title="http://dx.doi.org/10.1503%2Fcmaj.1050120" rel="nofollow">10.1503/cmaj.1050120</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16275976" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16275976">PMID 16275976</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>: <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1277053" class="external text" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1277053" rel="nofollow">1277053</a><span class="printonly">. <a href="http://www.cmaj.ca/cgi/content/full/173/10/1207-a" class="external free" title="http://www.cmaj.ca/cgi/content/full/173/10/1207-a" rel="nofollow">http://www.cmaj.ca/cgi/content/full/173/10/1207-a</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Questioning+the+benefits+of+statins&amp;rft.jtitle=CMAJ&amp;rft.aulast=Vos+E%2C+Rose+CP&amp;rft.au=Vos+E%2C+Rose+CP&amp;rft.date=November+2005&amp;rft.volume=173&amp;rft.issue=10&amp;rft.pages=1207%3B+author+reply+1210&amp;rft_id=info:doi/10.1503%2Fcmaj.1050120&amp;rft_id=info:pmid/16275976&amp;rft_id=http%3A%2F%2Fwww.cmaj.ca%2Fcgi%2Fcontent%2Ffull%2F173%2F10%2F1207-a&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-26"><b><a href="#cite_ref-26" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFT._E._Strandberg.2C_S._Lehto.2C_K._Py.C3.B6r.C3.A4l.C3.A4.2C_A._Kes.C3.A4niemi.2C_H._Oksa1997">T. E. Strandberg, S. Lehto, K. Pyörälä, A. Kesäniemi, H. Oksa (1997-01-11). "<a href="http://eurheartj.oxfordjournals.org/cgi/content/abstract/18/11/1725" class="external text" title="http://eurheartj.oxfordjournals.org/cgi/content/abstract/18/11/1725" rel="nofollow">Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland</a>". <i>European Heart Journal</i> <b>18</b> (18(11)): 1725–1727;. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9402446" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9402446">PMID 9402446</a><span class="printonly">. <a href="http://eurheartj.oxfordjournals.org/cgi/content/abstract/18/11/1725" class="external free" title="http://eurheartj.oxfordjournals.org/cgi/content/abstract/18/11/1725" rel="nofollow">http://eurheartj.oxfordjournals.org/cgi/content/abstract/18/11/1725</a></span><span class="reference-accessdate">. Retrieved on 2007-11-18</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cholesterol+lowering+after+participation+in+the+Scandinavian+Simvastatin+Survival+Study+%284S%29+in+Finland&amp;rft.jtitle=European+Heart+Journal&amp;rft.aulast=T.+E.+Strandberg%2C+S.+Lehto%2C+K.+Py%C3%B6r%C3%A4l%C3%A4%2C+A.+Kes%C3%A4niemi%2C+H.+Oksa&amp;rft.au=T.+E.+Strandberg%2C+S.+Lehto%2C+K.+Py%C3%B6r%C3%A4l%C3%A4%2C+A.+Kes%C3%A4niemi%2C+H.+Oksa&amp;rft.date=1997-01-11&amp;rft.volume=18&amp;rft.issue=18%2811%29&amp;rft.pages=1725%E2%80%931727%3B&amp;rft_id=info:pmid/9402446&amp;rft_id=http%3A%2F%2Feurheartj.oxfordjournals.org%2Fcgi%2Fcontent%2Fabstract%2F18%2F11%2F1725&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-ASTEROID-27"><b><a href="#cite_ref-ASTEROID_27-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFNissen_SE.2C_Nicholls_SJ.2C_Sipahi_I.2C_.27.27et_al.27.272006">Nissen SE, Nicholls SJ, Sipahi I, <i>et al</i> (2006). "<a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external text" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial</a>" (PDF). <i>JAMA</i> <b>295</b> (13): 1556–65. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.295.13.jpc60002" class="external text" title="http://dx.doi.org/10.1001%2Fjama.295.13.jpc60002" rel="nofollow">10.1001/jama.295.13.jpc60002</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16533939" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16533939">PMID 16533939</a><span class="printonly">. <a href="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" class="external free" title="http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite" rel="nofollow">http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&amp;keytype=finite</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effect+of+very+high-intensity+statin+therapy+on+regression+of+coronary+atherosclerosis%3A+the+ASTEROID+trial&amp;rft.jtitle=JAMA&amp;rft.aulast=Nissen+SE%2C+Nicholls+SJ%2C+Sipahi+I%2C+%27%27et+al%27%27&amp;rft.au=Nissen+SE%2C+Nicholls+SJ%2C+Sipahi+I%2C+%27%27et+al%27%27&amp;rft.date=2006&amp;rft.volume=295&amp;rft.issue=13&amp;rft.pages=1556%E2%80%9365&amp;rft_id=info:doi/10.1001%2Fjama.295.13.jpc60002&amp;rft_id=info:pmid/16533939&amp;rft_id=http%3A%2F%2Fjama.ama-assn.org%2Fcgi%2Freprint%2Fjama%3B295%2F13%2F1556.pdf%3Fijkey%3DMd42dlk7z9TzyL8%26keytype%3Dfinite&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-CAPS-28"><b><a href="#cite_ref-CAPS_28-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDowns_JR.2C_Clearfield_M.2C_Weis_S.2C_.27.27et_al.27.271998">Downs JR, Clearfield M, Weis S, <i>et al</i> (May 1998). "<a href="http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=9613910" class="external text" title="http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=9613910" rel="nofollow">Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study</a>". <i>JAMA&#160;: the journal of the American Medical Association</i> <b>279</b> (20): 1615–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.279.20.1615" class="external text" title="http://dx.doi.org/10.1001%2Fjama.279.20.1615" rel="nofollow">10.1001/jama.279.20.1615</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9613910" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9613910">PMID 9613910</a><span class="printonly">. <a href="http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=9613910" class="external free" title="http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=9613910" rel="nofollow">http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=9613910</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Primary+prevention+of+acute+coronary+events+with+lovastatin+in+men+and+women+with+average+cholesterol+levels%3A+results+of+AFCAPS%2FTexCAPS.+Air+Force%2FTexas+Coronary+Atherosclerosis+Prevention+Study&amp;rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&amp;rft.aulast=Downs+JR%2C+Clearfield+M%2C+Weis+S%2C+%27%27et+al%27%27&amp;rft.au=Downs+JR%2C+Clearfield+M%2C+Weis+S%2C+%27%27et+al%27%27&amp;rft.date=May+1998&amp;rft.volume=279&amp;rft.issue=20&amp;rft.pages=1615%E2%80%9322&amp;rft_id=info:doi/10.1001%2Fjama.279.20.1615&amp;rft_id=info:pmid/9613910&amp;rft_id=http%3A%2F%2Fjama.ama-assn.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D9613910&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid1985608-29"><b><a href="#cite_ref-pmid1985608_29-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBradford_RH.2C_Shear_CL.2C_Chremos_AN.2C_.27.27et_al.27.271991">Bradford RH, Shear CL, Chremos AN, <i>et al</i> (1991). "Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia". <i>Arch. Intern. Med.</i> <b>151</b> (1): 43–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Farchinte.151.1.43" class="external text" title="http://dx.doi.org/10.1001%2Farchinte.151.1.43" rel="nofollow">10.1001/archinte.151.1.43</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1985608" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1985608">PMID 1985608</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Expanded+Clinical+Evaluation+of+Lovastatin+%28EXCEL%29+study+results.+I.+Efficacy+in+modifying+plasma+lipoproteins+and+adverse+event+profile+in+8245+patients+with+moderate+hypercholesterolemia&amp;rft.jtitle=Arch.+Intern.+Med.&amp;rft.aulast=Bradford+RH%2C+Shear+CL%2C+Chremos+AN%2C+%27%27et+al%27%27&amp;rft.au=Bradford+RH%2C+Shear+CL%2C+Chremos+AN%2C+%27%27et+al%27%27&amp;rft.date=1991&amp;rft.volume=151&amp;rft.issue=1&amp;rft.pages=43%E2%80%939&amp;rft_id=info:doi/10.1001%2Farchinte.151.1.43&amp;rft_id=info:pmid/1985608&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15855581-30"><b><a href="#cite_ref-pmid15855581_30-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSever_PS.2C_Poulter_NR.2C_Dahl.C3.B6f_B.2C_.27.27et_al.27.272005">Sever PS, Poulter NR, Dahlöf B, <i>et al</i> (2005). "Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)". <i>Diabetes Care</i> <b>28</b> (5): 1151–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.2337%2Fdiacare.28.5.1151" class="external text" title="http://dx.doi.org/10.2337%2Fdiacare.28.5.1151" rel="nofollow">10.2337/diacare.28.5.1151</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15855581" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15855581">PMID 15855581</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Reduction+in+cardiovascular+events+with+atorvastatin+in+2%2C532+patients+with+type+2+diabetes%3A+Anglo-Scandinavian+Cardiac+Outcomes+Trial--lipid-lowering+arm+%28ASCOT-LLA%29&amp;rft.jtitle=Diabetes+Care&amp;rft.aulast=Sever+PS%2C+Poulter+NR%2C+Dahl%C3%B6f+B%2C+%27%27et+al%27%27&amp;rft.au=Sever+PS%2C+Poulter+NR%2C+Dahl%C3%B6f+B%2C+%27%27et+al%27%27&amp;rft.date=2005&amp;rft.volume=28&amp;rft.issue=5&amp;rft.pages=1151%E2%80%937&amp;rft_id=info:doi/10.2337%2Fdiacare.28.5.1151&amp;rft_id=info:pmid/15855581&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-31"><b><a href="#cite_ref-31" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFLinda_Brookes.2C_MSc">Linda Brookes, MSc. <a href="http://www.medscape.com/viewarticle/536377" class="external text" title="http://www.medscape.com/viewarticle/536377" rel="nofollow">"SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels"</a>. <a href="/wiki/Medscape" title="Medscape">Medscape</a><span class="printonly">. <a href="http://www.medscape.com/viewarticle/536377" class="external free" title="http://www.medscape.com/viewarticle/536377" rel="nofollow">http://www.medscape.com/viewarticle/536377</a></span><span class="reference-accessdate">. Retrieved on 2007-11-19</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=SPARCL%3A+Stroke+Prevention+by+Aggressive+Reduction+in+Cholesterol+Levels&amp;rft.atitle=&amp;rft.aulast=Linda+Brookes%2C+MSc&amp;rft.au=Linda+Brookes%2C+MSc&amp;rft.pub=%5B%5BMedscape%5D%5D&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F536377&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-32"><b><a href="#cite_ref-32" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFAmarenco_P.2C_Bogousslavsky_J.2C_Callahan_AS.2C_.27.27et_al.27.272003">Amarenco P, Bogousslavsky J, Callahan AS, <i>et al</i> (2003). "<a href="http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&amp;ProduktNr=224153&amp;ArtikelNr=72562" class="external text" title="http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&amp;ProduktNr=224153&amp;ArtikelNr=72562" rel="nofollow">Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study</a>". <i>Cerebrovascular diseases</i> <b>16</b> (4): 389–95. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1159%2F000072562" class="external text" title="http://dx.doi.org/10.1159%2F000072562" rel="nofollow">10.1159/000072562</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14584489" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14584489">PMID 14584489</a><span class="printonly">. <a href="http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&amp;ProduktNr=224153&amp;ArtikelNr=72562" class="external free" title="http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&amp;ProduktNr=224153&amp;ArtikelNr=72562" rel="nofollow">http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowAbstract&amp;ProduktNr=224153&amp;ArtikelNr=72562</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Design+and+baseline+characteristics+of+the+stroke+prevention+by+aggressive+reduction+in+cholesterol+levels+%28SPARCL%29+study&amp;rft.jtitle=Cerebrovascular+diseases&amp;rft.aulast=Amarenco+P%2C+Bogousslavsky+J%2C+Callahan+AS%2C+%27%27et+al%27%27&amp;rft.au=Amarenco+P%2C+Bogousslavsky+J%2C+Callahan+AS%2C+%27%27et+al%27%27&amp;rft.date=2003&amp;rft.volume=16&amp;rft.issue=4&amp;rft.pages=389%E2%80%9395&amp;rft_id=info:doi/10.1159%2F000072562&amp;rft_id=info:pmid/14584489&amp;rft_id=http%3A%2F%2Fcontent.karger.com%2FProdukteDB%2Fprodukte.asp%3FAktion%3DShowAbstract%26ProduktNr%3D224153%26ArtikelNr%3D72562&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-33"><b><a href="#cite_ref-33" title="">^</a></b> <a href="http://www.heartattackproof.com/resolving_cade.htm" class="external text" title="http://www.heartattackproof.com/resolving_cade.htm" rel="nofollow">Resolving the Coronary Artery Disease Epidemic through Plant-Based Nutrition</a> Caldwell B. Esselstyn, Jr., MD</li>
<li id="cite_note-34"><b><a href="#cite_ref-34" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGinter_E2007">Ginter E (2007). "Chronic vitamin C deficiency increases the risk of cardiovascular diseases". <i>Bratisl Lek Listy</i> <b>108</b> (9): 417–21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18225482" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18225482">PMID 18225482</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Chronic+vitamin+C+deficiency+increases+the+risk+of+cardiovascular+diseases&amp;rft.jtitle=Bratisl+Lek+Listy&amp;rft.aulast=Ginter+E&amp;rft.au=Ginter+E&amp;rft.date=2007&amp;rft.volume=108&amp;rft.issue=9&amp;rft.pages=417%E2%80%9321&amp;rft_id=info:pmid/18225482&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-35"><b><a href="#cite_ref-35" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFB.C3.B6hm_F.2C_Settergren_M.2C_Pernow_J2007">Böhm F, Settergren M, Pernow J (2007). "Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo". <i>Atherosclerosis</i> <b>190</b> (2): 408–15. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.atherosclerosis.2006.02.018" class="external text" title="http://dx.doi.org/10.1016%2Fj.atherosclerosis.2006.02.018" rel="nofollow">10.1016/j.atherosclerosis.2006.02.018</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16527283" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16527283">PMID 16527283</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Vitamin+C+blocks+vascular+dysfunction+and+release+of+interleukin-6+induced+by+endothelin-1+in+humans+in+vivo&amp;rft.jtitle=Atherosclerosis&amp;rft.aulast=B%C3%B6hm+F%2C+Settergren+M%2C+Pernow+J&amp;rft.au=B%C3%B6hm+F%2C+Settergren+M%2C+Pernow+J&amp;rft.date=2007&amp;rft.volume=190&amp;rft.issue=2&amp;rft.pages=408%E2%80%9315&amp;rft_id=info:doi/10.1016%2Fj.atherosclerosis.2006.02.018&amp;rft_id=info:pmid/16527283&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-36"><b><a href="#cite_ref-36" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSato_K.2C_Dohi_Y.2C_Kojima_M.2C_Miyagawa_K.2C_Takase_H.2C_Katada_E.2C_Suzuki_S.2006">Sato K, Dohi Y, Kojima M, Miyagawa K, Takase H, Katada E, Suzuki S. (2006). "<a href="http://www.ncbi.nlm.nih.gov/pubmed/16927536" class="external text" title="http://www.ncbi.nlm.nih.gov/pubmed/16927536" rel="nofollow">Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension</a>". <i>Arzneimittelforschung</i> <b>56</b> (7): 535–40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16927536" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16927536">PMID 16927536</a><span class="printonly">. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16927536" class="external free" title="http://www.ncbi.nlm.nih.gov/pubmed/16927536" rel="nofollow">http://www.ncbi.nlm.nih.gov/pubmed/16927536</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effects+of+ascorbic+acid+on+ambulatory+blood+pressure+in+elderly+patients+with+refractory+hypertension&amp;rft.jtitle=Arzneimittelforschung&amp;rft.aulast=Sato+K%2C+Dohi+Y%2C+Kojima+M%2C+Miyagawa+K%2C+Takase+H%2C+Katada+E%2C+Suzuki+S.&amp;rft.au=Sato+K%2C+Dohi+Y%2C+Kojima+M%2C+Miyagawa+K%2C+Takase+H%2C+Katada+E%2C+Suzuki+S.&amp;rft.date=2006&amp;rft.volume=56&amp;rft.issue=7&amp;rft.pages=535%E2%80%9340&amp;rft_id=info:pmid/16927536&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F16927536&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-37"><b><a href="#cite_ref-37" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGladys_Block.2C_Christopher_D_Jensen.2C_Edward_P_Norkus.2C_Mark_Hudes_and_Patricia_B_Crawford2008">Gladys Block, Christopher D Jensen, Edward P Norkus, Mark Hudes and Patricia B Crawford (2008). "<a href="http://www.nutritionj.com/content/7/1/35" class="external text" title="http://www.nutritionj.com/content/7/1/35" rel="nofollow">Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women</a>". <i>Nutrition Journal</i> <b>7</b> (35): 535–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1186%2F1475-2891-7-35" class="external text" title="http://dx.doi.org/10.1186%2F1475-2891-7-35" rel="nofollow">10.1186/1475-2891-7-35</a></span><span class="printonly">. <a href="http://www.nutritionj.com/content/7/1/35" class="external free" title="http://www.nutritionj.com/content/7/1/35" rel="nofollow">http://www.nutritionj.com/content/7/1/35</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Vitamin+C+in+plasma+is+inversely+related+to+blood+pressure+and+change+in+blood+pressure+during+the+previous+year+in+young+Black+and+White+women&amp;rft.jtitle=Nutrition+Journal&amp;rft.aulast=Gladys+Block%2C+Christopher+D+Jensen%2C+Edward+P+Norkus%2C+Mark+Hudes+and+Patricia+B+Crawford&amp;rft.au=Gladys+Block%2C+Christopher+D+Jensen%2C+Edward+P+Norkus%2C+Mark+Hudes+and+Patricia+B+Crawford&amp;rft.date=2008&amp;rft.volume=7&amp;rft.issue=35&amp;rft.pages=535%E2%80%9340&amp;rft_id=info:doi/10.1186%2F1475-2891-7-35&amp;rft_id=http%3A%2F%2Fwww.nutritionj.com%2Fcontent%2F7%2F1%2F35&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-38"><b><a href="#cite_ref-38" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBrian_A._Mullan.3B_Ian_S._Young.3B_Howard_Fee.3B_David_R._McCance2002">Brian A. Mullan; Ian S. Young; Howard Fee; David R. McCance (2002). "<a href="http://hyper.ahajournals.org/cgi/content/abstract/40/6/804" class="external text" title="http://hyper.ahajournals.org/cgi/content/abstract/40/6/804" rel="nofollow">Ascorbic Acid Reduces Blood Pressure and Arterial Stiffness in Type 2 Diabetes</a>". <i>Hypertension</i> <b>40</b>: 804. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1161%2F01.HYP.0000039961.13718.00" class="external text" title="http://dx.doi.org/10.1161%2F01.HYP.0000039961.13718.00" rel="nofollow">10.1161/01.HYP.0000039961.13718.00</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12468561" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12468561">PMID 12468561</a><span class="printonly">. <a href="http://hyper.ahajournals.org/cgi/content/abstract/40/6/804" class="external free" title="http://hyper.ahajournals.org/cgi/content/abstract/40/6/804" rel="nofollow">http://hyper.ahajournals.org/cgi/content/abstract/40/6/804</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Ascorbic+Acid+Reduces+Blood+Pressure+and+Arterial+Stiffness+in+Type+2+Diabetes&amp;rft.jtitle=Hypertension&amp;rft.aulast=Brian+A.+Mullan%3B+Ian+S.+Young%3B+Howard+Fee%3B+David+R.+McCance&amp;rft.au=Brian+A.+Mullan%3B+Ian+S.+Young%3B+Howard+Fee%3B+David+R.+McCance&amp;rft.date=2002&amp;rft.volume=40&amp;rft.pages=804&amp;rft_id=info:doi/10.1161%2F01.HYP.0000039961.13718.00&amp;rft_id=info:pmid/12468561&amp;rft_id=http%3A%2F%2Fhyper.ahajournals.org%2Fcgi%2Fcontent%2Fabstract%2F40%2F6%2F804&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-39"><b><a href="#cite_ref-39" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHJ_Harwood_Jr.2C_YJ_Greene_and_PW_Stacpoole1986">HJ Harwood Jr, YJ Greene and PW Stacpoole (05 Jun 1986). "<a href="http://www.jbc.org/cgi/reprint/261/16/7127" class="external text" title="http://www.jbc.org/cgi/reprint/261/16/7127" rel="nofollow">Inhibition of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by ascorbic acid. An effect mediated by the free radical monodehydroascorbate</a>". <i>J. Biol. Chem.</i> <b>261</b> (16): 7127–7135<span class="printonly">. <a href="http://www.jbc.org/cgi/reprint/261/16/7127" class="external free" title="http://www.jbc.org/cgi/reprint/261/16/7127" rel="nofollow">http://www.jbc.org/cgi/reprint/261/16/7127</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Inhibition+of+human+leukocyte+3-hydroxy-3-methylglutaryl+coenzyme+A+reductase+activity+by+ascorbic+acid.+An+effect+mediated+by+the+free+radical+monodehydroascorbate&amp;rft.jtitle=J.+Biol.+Chem.&amp;rft.aulast=HJ+Harwood+Jr%2C+YJ+Greene+and+PW+Stacpoole&amp;rft.au=HJ+Harwood+Jr%2C+YJ+Greene+and+PW+Stacpoole&amp;rft.date=05+Jun+1986&amp;rft.volume=261&amp;rft.issue=16&amp;rft.pages=7127%E2%80%937135&amp;rft_id=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Freprint%2F261%2F16%2F7127&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-40"><b><a href="#cite_ref-40" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDas_S.2C_Ray_R.2C_Snehlata.2C_Das_N.2C_Srivastava_LM2006">Das S, Ray R, Snehlata, Das N, Srivastava LM (2006). "<a href="http://www.ncbi.nlm.nih.gov/pubmed/16479321" class="external text" title="http://www.ncbi.nlm.nih.gov/pubmed/16479321" rel="nofollow">Effect of ascorbic acid on prevention of hypercholesterolemia induced atherosclerosis</a>". <i>Mol Cell Biochem</i> <b>285(1-2)</b>: 143–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1007%2Fs11010-005-9070-x" class="external text" title="http://dx.doi.org/10.1007%2Fs11010-005-9070-x" rel="nofollow">10.1007/s11010-005-9070-x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16479321" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16479321">PMID 16479321</a><span class="printonly">. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16479321" class="external free" title="http://www.ncbi.nlm.nih.gov/pubmed/16479321" rel="nofollow">http://www.ncbi.nlm.nih.gov/pubmed/16479321</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effect+of+ascorbic+acid+on+prevention+of+hypercholesterolemia+induced+atherosclerosis&amp;rft.jtitle=Mol+Cell+Biochem&amp;rft.aulast=Das+S%2C+Ray+R%2C+Snehlata%2C+Das+N%2C+Srivastava+LM&amp;rft.au=Das+S%2C+Ray+R%2C+Snehlata%2C+Das+N%2C+Srivastava+LM&amp;rft.date=2006&amp;rft.volume=285%281-2%29&amp;rft.pages=143%E2%80%937&amp;rft_id=info:doi/10.1007%2Fs11010-005-9070-x&amp;rft_id=info:pmid/16479321&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F16479321&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-41"><b><a href="#cite_ref-41" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKlenner_F.R.1974">Klenner F.R. (1974). "<a href="http://www.seanet.com/%7Ealexs/ascorbate/197x/klenner-fr-j_int_assn_prev_med-1974-v1-n1-p45.htm" class="external text" title="http://www.seanet.com/%7Ealexs/ascorbate/197x/klenner-fr-j_int_assn_prev_med-1974-v1-n1-p45.htm" rel="nofollow">Significance of high daily intake of ascorbic acid in preventive medicine</a>". <i>J. Int. Acad. Prev. Med.</i> <b>1</b>: 45–49<span class="printonly">. <a href="http://www.seanet.com/%7Ealexs/ascorbate/197x/klenner-fr-j_int_assn_prev_med-1974-v1-n1-p45.htm" class="external free" title="http://www.seanet.com/%7Ealexs/ascorbate/197x/klenner-fr-j_int_assn_prev_med-1974-v1-n1-p45.htm" rel="nofollow">http://www.seanet.com/%7Ealexs/ascorbate/197x/klenner-fr-j_int_assn_prev_med-1974-v1-n1-p45.htm</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Significance+of+high+daily+intake+of+ascorbic+acid+in+preventive+medicine&amp;rft.jtitle=J.+Int.+Acad.+Prev.+Med.&amp;rft.aulast=Klenner+F.R.&amp;rft.au=Klenner+F.R.&amp;rft.date=1974&amp;rft.volume=1&amp;rft.pages=45%E2%80%9349&amp;rft_id=http%3A%2F%2Fwww.seanet.com%2F%257Ealexs%2Fascorbate%2F197x%2Fklenner-fr-j_int_assn_prev_med-1974-v1-n1-p45.htm&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-42"><b><a href="#cite_ref-42" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFStone.2C_I.1972">Stone, I. (1972). <i><a href="http://www.roccomanzi.it/IMP-VITAMINERALI/SCIENZIATI/scienziati-docu/stone/HEALINGFACTVitaC-TUTTO-ING_file/HEALINGFACTVitaC-TUTTO-ING.htm" class="external text" title="http://www.roccomanzi.it/IMP-VITAMINERALI/SCIENZIATI/scienziati-docu/stone/HEALINGFACTVitaC-TUTTO-ING_file/HEALINGFACTVitaC-TUTTO-ING.htm" rel="nofollow">The Healing Factor: Vitamin C Against Disease</a></i>. Grosset and Dunlap, New York/Perigee Books, published by The Putnam Publishing Group. <a href="/wiki/Special:BookSources/0399507647" class="internal">ISBN 0-399-50764-7</a><span class="printonly">. <a href="http://www.roccomanzi.it/IMP-VITAMINERALI/SCIENZIATI/scienziati-docu/stone/HEALINGFACTVitaC-TUTTO-ING_file/HEALINGFACTVitaC-TUTTO-ING.htm" class="external free" title="http://www.roccomanzi.it/IMP-VITAMINERALI/SCIENZIATI/scienziati-docu/stone/HEALINGFACTVitaC-TUTTO-ING_file/HEALINGFACTVitaC-TUTTO-ING.htm" rel="nofollow">http://www.roccomanzi.it/IMP-VITAMINERALI/SCIENZIATI/scienziati-docu/stone/HEALINGFACTVitaC-TUTTO-ING_file/HEALINGFACTVitaC-TUTTO-ING.htm</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Healing+Factor%3A+Vitamin+C+Against+Disease&amp;rft.aulast=Stone%2C+I.&amp;rft.au=Stone%2C+I.&amp;rft.date=1972&amp;rft.pub=Grosset+and+Dunlap%2C+New+York%2FPerigee+Books%2C+published+by+The+Putnam+Publishing+Group&amp;rft.isbn=0-399-50764-7&amp;rft_id=http%3A%2F%2Fwww.roccomanzi.it%2FIMP-VITAMINERALI%2FSCIENZIATI%2Fscienziati-docu%2Fstone%2FHEALINGFACTVitaC-TUTTO-ING_file%2FHEALINGFACTVitaC-TUTTO-ING.htm&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-43"><b><a href="#cite_ref-43" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRath_M.2C_Pauling_L1992">Rath M, Pauling L (1992). "<a href="http://www.orthomolecular.org/library/jom/1992/pdf/1992-v07n01-p005.pdf" class="external text" title="http://www.orthomolecular.org/library/jom/1992/pdf/1992-v07n01-p005.pdf" rel="nofollow">A Unified Theory of Human Cardiovascular Disease Leading the Way to the Abolition of This Disease as a Cause for Human Mortality</a>". <i>Journal of Orthomolecular Medicine</i> <b>7</b> (1): 5–15<span class="printonly">. <a href="http://www.orthomolecular.org/library/jom/1992/pdf/1992-v07n01-p005.pdf" class="external free" title="http://www.orthomolecular.org/library/jom/1992/pdf/1992-v07n01-p005.pdf" rel="nofollow">http://www.orthomolecular.org/library/jom/1992/pdf/1992-v07n01-p005.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+Unified+Theory+of+Human+Cardiovascular+Disease+Leading+the+Way+to+the+Abolition+of+This+Disease+as+a+Cause+for+Human+Mortality&amp;rft.jtitle=Journal+of+Orthomolecular+Medicine&amp;rft.aulast=Rath+M%2C+Pauling+L&amp;rft.au=Rath+M%2C+Pauling+L&amp;rft.date=1992&amp;rft.volume=7&amp;rft.issue=1&amp;rft.pages=5%E2%80%9315&amp;rft_id=http%3A%2F%2Fwww.orthomolecular.org%2Flibrary%2Fjom%2F1992%2Fpdf%2F1992-v07n01-p005.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-44"><b><a href="#cite_ref-44" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRobinson_I.2C_de_Serna_DG.2C_Gutierrez_A.2C_Schade_DS2006">Robinson I, de Serna DG, Gutierrez A, Schade DS (2006). "Vitamin E in humans: an explanation of clinical trial failure". <i>Endocr Pract</i> <b>12</b> (5): 576–82. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17002935" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17002935">PMID 17002935</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Vitamin+E+in+humans%3A+an+explanation+of+clinical+trial+failure&amp;rft.jtitle=Endocr+Pract&amp;rft.aulast=Robinson+I%2C+de+Serna+DG%2C+Gutierrez+A%2C+Schade+DS&amp;rft.au=Robinson+I%2C+de+Serna+DG%2C+Gutierrez+A%2C+Schade+DS&amp;rft.date=2006&amp;rft.volume=12&amp;rft.issue=5&amp;rft.pages=576%E2%80%9382&amp;rft_id=info:pmid/17002935&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-45"><b><a href="#cite_ref-45" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGeleijnse_JM.2C_Vermeer_C.2C_Grobbee_DE.2C_.27.27et_al.27.272004">Geleijnse JM, Vermeer C, Grobbee DE, <i>et al</i> (2004). "Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study". <i>J. Nutr.</i> <b>134</b> (11): 3100–5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15514282" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15514282">PMID 15514282</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dietary+intake+of+menaquinone+is+associated+with+a+reduced+risk+of+coronary+heart+disease%3A+the+Rotterdam+Study&amp;rft.jtitle=J.+Nutr.&amp;rft.aulast=Geleijnse+JM%2C+Vermeer+C%2C+Grobbee+DE%2C+%27%27et+al%27%27&amp;rft.au=Geleijnse+JM%2C+Vermeer+C%2C+Grobbee+DE%2C+%27%27et+al%27%27&amp;rft.date=2004&amp;rft.volume=134&amp;rft.issue=11&amp;rft.pages=3100%E2%80%935&amp;rft_id=info:pmid/15514282&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-46"><b><a href="#cite_ref-46" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFErkkil.C3.A4_AT.2C_Booth_SL2008">Erkkilä AT, Booth SL (2008). "Vitamin K intake and atherosclerosis". <i>Curr. Opin. Lipidol.</i> <b>19</b> (1): 39–42. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2FMOL.0b013e3282f1c57f" class="external text" title="http://dx.doi.org/10.1097%2FMOL.0b013e3282f1c57f" rel="nofollow">10.1097/MOL.0b013e3282f1c57f</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18196985" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18196985">PMID 18196985</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Vitamin+K+intake+and+atherosclerosis&amp;rft.jtitle=Curr.+Opin.+Lipidol.&amp;rft.aulast=Erkkil%C3%A4+AT%2C+Booth+SL&amp;rft.au=Erkkil%C3%A4+AT%2C+Booth+SL&amp;rft.date=2008&amp;rft.volume=19&amp;rft.issue=1&amp;rft.pages=39%E2%80%9342&amp;rft_id=info:doi/10.1097%2FMOL.0b013e3282f1c57f&amp;rft_id=info:pmid/18196985&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-47"><b><a href="#cite_ref-47" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWallin_R.2C_Schurgers_L.2C_Wajih_N2008">Wallin R, Schurgers L, Wajih N (2008). "Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification". <i>Thromb. Res.</i> <b>122</b>: 411. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.thromres.2007.12.005" class="external text" title="http://dx.doi.org/10.1016%2Fj.thromres.2007.12.005" rel="nofollow">10.1016/j.thromres.2007.12.005</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18234293" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18234293">PMID 18234293</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effects+of+the+blood+coagulation+vitamin+K+as+an+inhibitor+of+arterial+calcification&amp;rft.jtitle=Thromb.+Res.&amp;rft.aulast=Wallin+R%2C+Schurgers+L%2C+Wajih+N&amp;rft.au=Wallin+R%2C+Schurgers+L%2C+Wajih+N&amp;rft.date=2008&amp;rft.volume=122&amp;rft.pages=411&amp;rft_id=info:doi/10.1016%2Fj.thromres.2007.12.005&amp;rft_id=info:pmid/18234293&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17259340-48"><b><a href="#cite_ref-pmid17259340_48-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBrewer_GJ2007">Brewer GJ (2007). "Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease". <i>Exp. Biol. Med. (Maywood)</i> <b>232</b> (2): 323–35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17259340" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17259340">PMID 17259340</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Iron+and+copper+toxicity+in+diseases+of+aging%2C+particularly+atherosclerosis+and+Alzheimer%27s+disease&amp;rft.jtitle=Exp.+Biol.+Med.+%28Maywood%29&amp;rft.aulast=Brewer+GJ&amp;rft.au=Brewer+GJ&amp;rft.date=2007&amp;rft.volume=232&amp;rft.issue=2&amp;rft.pages=323%E2%80%9335&amp;rft_id=info:pmid/17259340&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17685184-49"><b><a href="#cite_ref-pmid17685184_49-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSullivan_JL.2C_Mascitelli_L2007">Sullivan JL, Mascitelli L (2007). "[Current status of the iron hypothesis of cardiovascular diseases]" (in Italian). <i>Recenti Prog Med</i> <b>98</b> (7-8): 373–7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17685184" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17685184">PMID 17685184</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=%5BCurrent+status+of+the+iron+hypothesis+of+cardiovascular+diseases%5D&amp;rft.jtitle=Recenti+Prog+Med&amp;rft.aulast=Sullivan+JL%2C+Mascitelli+L&amp;rft.au=Sullivan+JL%2C+Mascitelli+L&amp;rft.date=2007&amp;rft.volume=98&amp;rft.issue=7-8&amp;rft.pages=373%E2%80%937&amp;rft_id=info:pmid/17685184&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17299195-50"><b><a href="#cite_ref-pmid17299195_50-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFZacharski_LR.2C_Chow_BK.2C_Howes_PS.2C_.27.27et_al.27.272007">Zacharski LR, Chow BK, Howes PS, <i>et al</i> (2007). "Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial". <i>JAMA</i> <b>297</b> (6): 603–10. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.297.6.603" class="external text" title="http://dx.doi.org/10.1001%2Fjama.297.6.603" rel="nofollow">10.1001/jama.297.6.603</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17299195" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17299195">PMID 17299195</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Reduction+of+iron+stores+and+cardiovascular+outcomes+in+patients+with+peripheral+arterial+disease%3A+a+randomized+controlled+trial&amp;rft.jtitle=JAMA&amp;rft.aulast=Zacharski+LR%2C+Chow+BK%2C+Howes+PS%2C+%27%27et+al%27%27&amp;rft.au=Zacharski+LR%2C+Chow+BK%2C+Howes+PS%2C+%27%27et+al%27%27&amp;rft.date=2007&amp;rft.volume=297&amp;rft.issue=6&amp;rft.pages=603%E2%80%9310&amp;rft_id=info:doi/10.1001%2Fjama.297.6.603&amp;rft_id=info:pmid/17299195&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-51"><b><a href="#cite_ref-51" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.cypherusa.com/cypher-j2ee/cypherjsp/main_splash/stent.jsp" class="external text" title="http://www.cypherusa.com/cypher-j2ee/cypherjsp/main_splash/stent.jsp" rel="nofollow">"Heart disease and stents"</a>. <a href="/wiki/Cypher_Stent" title="Cypher Stent" class="mw-redirect">Cypher Stent</a><span class="printonly">. <a href="http://www.cypherusa.com/cypher-j2ee/cypherjsp/main_splash/stent.jsp" class="external free" title="http://www.cypherusa.com/cypher-j2ee/cypherjsp/main_splash/stent.jsp" rel="nofollow">http://www.cypherusa.com/cypher-j2ee/cypherjsp/main_splash/stent.jsp</a></span><span class="reference-accessdate">. Retrieved on 2008-04-01</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Heart+disease+and+stents&amp;rft.atitle=&amp;rft.pub=%5B%5BCypher+Stent%5D%5D&amp;rft_id=http%3A%2F%2Fwww.cypherusa.com%2Fcypher-j2ee%2Fcypherjsp%2Fmain_splash%2Fstent.jsp&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Polypill-52"><b><a href="#cite_ref-Polypill_52-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWald_NJ.2C_Law_MR2003">Wald NJ, Law MR (June 2003). "<a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=162259" class="external text" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=162259" rel="nofollow">A strategy to reduce cardiovascular disease by more than 80%</a>". <i><a href="/wiki/British_Medical_Journal" title="British Medical Journal" class="mw-redirect">BMJ</a> (Clinical research ed.)</i> <b>326</b> (7404): 1419. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1136%2Fbmj.326.7404.1419" class="external text" title="http://dx.doi.org/10.1136%2Fbmj.326.7404.1419" rel="nofollow">10.1136/bmj.326.7404.1419</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12829553" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12829553">PMID 12829553</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+strategy+to+reduce+cardiovascular+disease+by+more+than+80%25&amp;rft.jtitle=%5B%5BBritish+Medical+Journal%7CBMJ%5D%5D+%28Clinical+research+ed.%29&amp;rft.aulast=Wald+NJ%2C+Law+MR&amp;rft.au=Wald+NJ%2C+Law+MR&amp;rft.date=June+2003&amp;rft.volume=326&amp;rft.issue=7404&amp;rft.pages=1419&amp;rft_id=info:doi/10.1136%2Fbmj.326.7404.1419&amp;rft_id=info:pmid/12829553&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-53"><b><a href="#cite_ref-53" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPrice_PA.2C_Faus_SA.2C_Williamson_MK2000">Price PA, Faus SA, Williamson MK (February 2000). "<a href="http://atvb.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=10669626" class="external text" title="http://atvb.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=10669626" rel="nofollow">Warfarin-induced artery calcification is accelerated by growth and vitamin D</a>". <i>Arteriosclerosis, thrombosis, and vascular biology</i> <b>20</b> (2): 317–27. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10669626" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10669626">PMID 10669626</a><span class="printonly">. <a href="http://atvb.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=10669626" class="external free" title="http://atvb.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=10669626" rel="nofollow">http://atvb.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=10669626</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Warfarin-induced+artery+calcification+is+accelerated+by+growth+and+vitamin+D&amp;rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&amp;rft.aulast=Price+PA%2C+Faus+SA%2C+Williamson+MK&amp;rft.au=Price+PA%2C+Faus+SA%2C+Williamson+MK&amp;rft.date=February+2000&amp;rft.volume=20&amp;rft.issue=2&amp;rft.pages=317%E2%80%9327&amp;rft_id=info:pmid/10669626&amp;rft_id=http%3A%2F%2Fatvb.ahajournals.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D10669626&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-54"><b><a href="#cite_ref-54" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGeleijnse_JM.2C_Vermeer_C.2C_Grobbee_DE.2C_.27.27et_al.27.272004">Geleijnse JM, Vermeer C, Grobbee DE, <i>et al</i> (November 2004). "<a href="http://jn.nutrition.org/cgi/content/full/134/11/3100" class="external text" title="http://jn.nutrition.org/cgi/content/full/134/11/3100" rel="nofollow">Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study</a>". <i>J Nutr.</i> <b>134</b> (11): 3100–5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15514282" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15514282">PMID 15514282</a><span class="printonly">. <a href="http://jn.nutrition.org/cgi/content/full/134/11/3100" class="external free" title="http://jn.nutrition.org/cgi/content/full/134/11/3100" rel="nofollow">http://jn.nutrition.org/cgi/content/full/134/11/3100</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dietary+intake+of+menaquinone+is+associated+with+a+reduced+risk+of+coronary+heart+disease%3A+the+Rotterdam+Study&amp;rft.jtitle=J+Nutr.&amp;rft.aulast=Geleijnse+JM%2C+Vermeer+C%2C+Grobbee+DE%2C+%27%27et+al%27%27&amp;rft.au=Geleijnse+JM%2C+Vermeer+C%2C+Grobbee+DE%2C+%27%27et+al%27%27&amp;rft.date=November+2004&amp;rft.volume=134&amp;rft.issue=11&amp;rft.pages=3100%E2%80%935&amp;rft_id=info:pmid/15514282&amp;rft_id=http%3A%2F%2Fjn.nutrition.org%2Fcgi%2Fcontent%2Ffull%2F134%2F11%2F3100&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-55"><b><a href="#cite_ref-55" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBarter_PJ.2C_Caulfield_M.2C_Eriksson_M.2C_.27.27et_al.27.272007">Barter PJ, Caulfield M, Eriksson M, <i>et al</i> (November 2007). "<a href="http://content.nejm.org/cgi/content/full/NEJMoa0706628" class="external text" title="http://content.nejm.org/cgi/content/full/NEJMoa0706628" rel="nofollow">Effects of torcetrapib in patients at high risk for coronary events</a>". <i>N Engl J Med.</i> <b>357</b> (21): 2109–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa0706628" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa0706628" rel="nofollow">10.1056/NEJMoa0706628</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17984165" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17984165">PMID 17984165</a><span class="printonly">. <a href="http://content.nejm.org/cgi/content/full/NEJMoa0706628" class="external free" title="http://content.nejm.org/cgi/content/full/NEJMoa0706628" rel="nofollow">http://content.nejm.org/cgi/content/full/NEJMoa0706628</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effects+of+torcetrapib+in+patients+at+high+risk+for+coronary+events&amp;rft.jtitle=N+Engl+J+Med.&amp;rft.aulast=Barter+PJ%2C+Caulfield+M%2C+Eriksson+M%2C+%27%27et+al%27%27&amp;rft.au=Barter+PJ%2C+Caulfield+M%2C+Eriksson+M%2C+%27%27et+al%27%27&amp;rft.date=November+2007&amp;rft.volume=357&amp;rft.issue=21&amp;rft.pages=2109%E2%80%9322&amp;rft_id=info:doi/10.1056%2FNEJMoa0706628&amp;rft_id=info:pmid/17984165&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2FNEJMoa0706628&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Hughes-56"><b><a href="#cite_ref-Hughes_56-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFSue_Hughes2007">Sue Hughes (March 26, 2007). <a href="http://www.theheart.org/article/779839.do" class="external text" title="http://www.theheart.org/article/779839.do" rel="nofollow">"ERASE: New HDL mimetic shows promise"</a>. HeartWire<span class="printonly">. <a href="http://www.theheart.org/article/779839.do" class="external free" title="http://www.theheart.org/article/779839.do" rel="nofollow">http://www.theheart.org/article/779839.do</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=ERASE%3A+New+HDL+mimetic+shows+promise&amp;rft.atitle=&amp;rft.aulast=Sue+Hughes&amp;rft.au=Sue+Hughes&amp;rft.date=March+26%2C+2007&amp;rft.pub=HeartWire&amp;rft_id=http%3A%2F%2Fwww.theheart.org%2Farticle%2F779839.do&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Nilsson-57"><b><a href="#cite_ref-Nilsson_57-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFJan_Nilsson.3B_G.C3.B6ran_K._Hansson.3B_Prediman_K._Shah2005">Jan Nilsson; Göran K. Hansson; Prediman K. Shah (2005). "<a href="http://atvb.ahajournals.org/cgi/content/abstract/atvbaha;25/1/18" class="external text" title="http://atvb.ahajournals.org/cgi/content/abstract/atvbaha;25/1/18" rel="nofollow">Immunomodulation of Atherosclerosis – Implications for Vaccine Development—ATVB In Focus</a>". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> <b>5</b>: 18–28. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1161%2F01.ATV.0000149142.42590.a2" class="external text" title="http://dx.doi.org/10.1161%2F01.ATV.0000149142.42590.a2" rel="nofollow">10.1161/01.ATV.0000149142.42590.a2</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15514204" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15514204">PMID 15514204</a><span class="printonly">. <a href="http://atvb.ahajournals.org/cgi/content/abstract/atvbaha;25/1/18" class="external free" title="http://atvb.ahajournals.org/cgi/content/abstract/atvbaha;25/1/18" rel="nofollow">http://atvb.ahajournals.org/cgi/content/abstract/atvbaha;25/1/18</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Immunomodulation+of+Atherosclerosis+%E2%80%93+Implications+for+Vaccine+Development%E2%80%94ATVB+In+Focus&amp;rft.jtitle=Arteriosclerosis%2C+Thrombosis%2C+and+Vascular+Biology&amp;rft.aulast=Jan+Nilsson%3B+G%C3%B6ran+K.+Hansson%3B+Prediman+K.+Shah&amp;rft.au=Jan+Nilsson%3B+G%C3%B6ran+K.+Hansson%3B+Prediman+K.+Shah&amp;rft.date=2005&amp;rft.volume=5&amp;rft.pages=18%E2%80%9328&amp;rft_id=info:doi/10.1161%2F01.ATV.0000149142.42590.a2&amp;rft_id=info:pmid/15514204&amp;rft_id=http%3A%2F%2Fatvb.ahajournals.org%2Fcgi%2Fcontent%2Fabstract%2Fatvbaha%3B25%2F1%2F18&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-58"><b><a href="#cite_ref-58" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFM_Stitzinger2007">M Stitzinger (2007). <a href="https://openaccess.leidenuniv.nl/dspace/bitstream/1887/9729/11/01.pdf" class="external text" title="https://openaccess.leidenuniv.nl/dspace/bitstream/1887/9729/11/01.pdf" rel="nofollow">"Lipids, inflammation and atherosclerosis"</a> (pdf). The digital repository of Leiden University<span class="printonly">. <a href="https://openaccess.leidenuniv.nl/dspace/bitstream/1887/9729/11/01.pdf" class="external free" title="https://openaccess.leidenuniv.nl/dspace/bitstream/1887/9729/11/01.pdf" rel="nofollow">https://openaccess.leidenuniv.nl/dspace/bitstream/1887/9729/11/01.pdf</a></span><span class="reference-accessdate">. Retrieved on 2007-11-02</span>.  "Results of clinical trials investigating anti-chlamydial antibiotics as an addition to standard therapy in patients with coronary artery disease have been inconsistent. Therefore, Andraws et al. conducted a meta- analysis of these clinical trials and found that evidence available to date does not demonstrate an overall benefit of antibiotic therapy in reducing mortality or cardiovascular events in patients with coronary artery disease."</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Lipids%2C+inflammation+and+atherosclerosis&amp;rft.atitle=&amp;rft.aulast=M+Stitzinger&amp;rft.au=M+Stitzinger&amp;rft.date=2007&amp;rft.pub=The+digital+repository+of+Leiden+University&amp;rft_id=https%3A%2F%2Fopenaccess.leidenuniv.nl%2Fdspace%2Fbitstream%2F1887%2F9729%2F11%2F01.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Atherosclerosis"><span style="display: none;">&#160;</span></span></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Atherosclerosis&amp;action=edit&amp;section=24" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.dmoz.org/Health/Conditions_and_Diseases/Cardiovascular_Disorders/Vascular_Disorders/Atherosclerosis//" class="external text" title="http://www.dmoz.org/Health/Conditions_and_Diseases/Cardiovascular_Disorders/Vascular_Disorders/Atherosclerosis//" rel="nofollow">Atherosclerosis</a> at the <a href="/wiki/Open_Directory_Project" title="Open Directory Project">Open Directory Project</a></li>
</ul>
<p><br /></p>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";background:Silver" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;background:Silver;border:none;; font-size:xx-small;"><a href="/wiki/Template:Vascular_diseases" title="Template:Vascular diseases"><span title="View this template" style=";background:Silver;border:none;">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="/wiki/Template_talk:Vascular_diseases" title="Template talk:Vascular diseases"><span title="Discussion about this template" style=";background:Silver;border:none;">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:Vascular_diseases&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:Vascular_diseases&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";background:Silver;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="/wiki/Cardiovascular_disease" title="Cardiovascular disease">Cardiovascular disease</a>: <a href="/wiki/Vascular_disease" title="Vascular disease">vascular disease</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Circulatory_system" title="Circulatory system">Circulatory system</a> <a href="/wiki/Pathology" title="Pathology">pathology</a> (<a href="/wiki/ICD-10_Chapter_IX:_Diseases_of_the_circulatory_system#.28I70-I79.29_Diseases_of_arteries.2C_arterioles_and_capillaries" title="ICD-10 Chapter IX: Diseases of the circulatory system">I70-I99</a>, <a href="/wiki/List_of_ICD-9_codes_390-459:_Diseases_of_the_circulatory_system#diseases_of_arteries.2C_arterioles.2C_and_capillaries_.28440-448.29" title="List of ICD-9 codes 390-459: Diseases of the circulatory system" class="mw-redirect">440-459</a>)</span></th>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Arteries" title="Arteries" class="mw-redirect">Arteries</a>, <a href="/wiki/Arterioles" title="Arterioles" class="mw-redirect">arterioles</a><br />
and <a href="/wiki/Capillaries" title="Capillaries" class="mw-redirect">capillaries</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Inflammation" title="Inflammation">Inflammation</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Arteritis" title="Arteritis">Arteritis</a> (<a href="/wiki/Aortitis" title="Aortitis">Aortitis</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Buerger%27s_disease" title="Buerger's disease">Buerger's disease</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Arterial_occlusive_disease" title="Arterial occlusive disease" class="mw-redirect">Arterial occlusive disease</a>/<br />
<a href="/wiki/Peripheral_vascular_disease" title="Peripheral vascular disease">peripheral vascular disease</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Arteriosclerosis" title="Arteriosclerosis">Arteriosclerosis</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><strong class="selflink">Atherosclerosis</strong> (<a href="/wiki/Foam_cells" title="Foam cells">Foam cells</a>, <a href="/wiki/Fatty_streak" title="Fatty streak">Fatty streak</a>, <a href="/wiki/Atheroma" title="Atheroma">Atheroma</a>, <a href="/wiki/Intermittent_claudication" title="Intermittent claudication">Intermittent claudication</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Monckeberg%27s_arteriosclerosis" title="Monckeberg's arteriosclerosis">Monckeberg's arteriosclerosis</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Arteriolosclerosis" title="Arteriolosclerosis">Arteriolosclerosis</a> (<a href="/wiki/Hyaline_arteriolosclerosis" title="Hyaline arteriolosclerosis">Hyaline</a>, <a href="/wiki/Hyperplastic_arteriolosclerosis" title="Hyperplastic arteriolosclerosis">Hyperplastic</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Stenosis" title="Stenosis">Stenosis</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Renal_artery_stenosis" title="Renal artery stenosis">Renal artery stenosis</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Carotid_artery_stenosis" title="Carotid artery stenosis">Carotid artery stenosis</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;">Other</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Fibromuscular_dysplasia" title="Fibromuscular dysplasia">Fibromuscular dysplasia</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Degos_disease" title="Degos disease">Degos disease</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Aortoiliac_occlusive_disease" title="Aortoiliac occlusive disease">Aortoiliac occlusive disease</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Raynaud%27s_phenomenon" title="Raynaud's phenomenon">Raynaud's phenomenon</a>/<a href="/wiki/Raynaud%27s_disease" title="Raynaud's disease">Raynaud's disease</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Erythromelalgia" title="Erythromelalgia">Erythromelalgia</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Aneurysm" title="Aneurysm">Aneurysm</a>/<a href="/wiki/Dissection_(medical)" title="Dissection (medical)">dissection</a>/<br />
<a href="/wiki/Pseudoaneurysm" title="Pseudoaneurysm">pseudoaneurysm</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em">torso: <a href="/wiki/Aortic_aneurysm" title="Aortic aneurysm">Aortic aneurysm</a> (<a href="/wiki/Thoracic_aortic_aneurysm" title="Thoracic aortic aneurysm">Thoracic aortic aneurysm</a>, <a href="/wiki/Abdominal_aortic_aneurysm" title="Abdominal aortic aneurysm">Abdominal aortic aneurysm</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Aortic_dissection" title="Aortic dissection">Aortic dissection</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Coronary_artery_aneurysm" title="Coronary artery aneurysm">Coronary artery aneurysm</a><br />
head/neck: <a href="/wiki/Cerebral_aneurysm" title="Cerebral aneurysm">Cerebral aneurysm</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Intracranial_berry_aneurysm" title="Intracranial berry aneurysm">Intracranial berry aneurysm</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Carotid_artery_dissection" title="Carotid artery dissection">Carotid artery dissection</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Vertebral_artery_dissection" title="Vertebral artery dissection">Vertebral artery dissection</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Familial_aortic_dissection" title="Familial aortic dissection">Familial aortic dissection</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Vascular_malformation" title="Vascular malformation">Vascular malformation</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Arteriovenous_fistula" title="Arteriovenous fistula">Arteriovenous fistula</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Hereditary_hemorrhagic_telangiectasia" title="Hereditary hemorrhagic telangiectasia">Hereditary hemorrhagic telangiectasia</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Nevus#Vascular_nevus" title="Nevus">Vascular nevus</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Spider_angioma" title="Spider angioma">Spider angioma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Halo_nevus" title="Halo nevus">Halo nevus</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Cherry_angioma" title="Cherry angioma">Cherry angioma</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Vein" title="Vein">Veins</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Inflammation" title="Inflammation">Inflammation</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Phlebitis" title="Phlebitis">Phlebitis</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Venous_thrombosis" title="Venous thrombosis">Venous thrombosis</a>/<br />
<a href="/wiki/Thrombophlebitis" title="Thrombophlebitis">Thrombophlebitis</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i>primarily lower limb</i> (<a href="/wiki/Deep_vein_thrombosis" title="Deep vein thrombosis">Deep vein thrombosis</a>)
<p><i>abdomen</i> (<a href="/wiki/May-Thurner_syndrome" title="May-Thurner syndrome">May-Thurner syndrome</a>, <a href="/wiki/Portal_vein_thrombosis" title="Portal vein thrombosis">Portal vein thrombosis</a>, <a href="/wiki/Budd-Chiari_syndrome" title="Budd-Chiari syndrome">Budd-Chiari syndrome</a>, <a href="/wiki/Renal_vein_thrombosis" title="Renal vein thrombosis">Renal vein thrombosis</a>)</p>
<p><i>upper limb/torso</i> (<a href="/wiki/Paget-Schroetter_disease" title="Paget-Schroetter disease">Paget-Schroetter disease</a>, <a href="/wiki/Mondor%27s_disease" title="Mondor's disease">Mondor's disease</a>)</p>
<p><i>head</i> (<a href="/wiki/Cerebral_venous_sinus_thrombosis" title="Cerebral venous sinus thrombosis">Cerebral venous sinus thrombosis</a>)</p>
<a href="/wiki/Post-thrombotic_syndrome" title="Post-thrombotic syndrome">Post-thrombotic syndrome</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Varicose_veins" title="Varicose veins">Varicose veins</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Varicocele" title="Varicocele">Varicocele</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Gastric_varices" title="Gastric varices">Gastric varices</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Portacaval_anastomosis" title="Portacaval anastomosis">Portacaval anastomosis</a> (<a href="/wiki/Hemorrhoid" title="Hemorrhoid">Hemorrhoid</a>, <a href="/wiki/Esophageal_varices" title="Esophageal varices">Esophageal varices</a>, <a href="/wiki/Caput_medusae" title="Caput medusae">Caput medusae</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;">Other</div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Superior_vena_cava_syndrome" title="Superior vena cava syndrome">Superior vena cava syndrome</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Inferior_vena_cava_syndrome" title="Inferior vena cava syndrome">Inferior vena cava syndrome</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Venous_ulcer" title="Venous ulcer">Venous ulcer</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;">Arteries or veins</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Vasculitis" title="Vasculitis">Vasculitis</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Thrombosis" title="Thrombosis">Thrombosis</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Embolism" title="Embolism">Embolism</a> (<a href="/wiki/Pulmonary_embolism" title="Pulmonary embolism">Pulmonary embolism</a>, <a href="/wiki/Cholesterol_embolism" title="Cholesterol embolism">Cholesterol embolism</a>, <a href="/wiki/Paradoxical_embolism" title="Paradoxical embolism">Paradoxical embolism</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Angiopathy" title="Angiopathy">Angiopathy</a> (<a href="/wiki/Macroangiopathy" title="Macroangiopathy">Macroangiopathy</a>, <a href="/wiki/Microangiopathy" title="Microangiopathy">Microangiopathy</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Lymphatic_disease" title="Lymphatic disease">Lymphatic disease</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Lymphadenopathy" title="Lymphadenopathy">Lymphadenitis</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Lymphangitis" title="Lymphangitis">Lymphangitis</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Lymphedema" title="Lymphedema">Lymphedema</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:MistyRose;;"><a href="/wiki/Blood_pressure" title="Blood pressure">Blood pressure</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Hypertension" title="Hypertension">Hypertension</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Hypertensive_heart_disease" title="Hypertensive heart disease">Hypertensive heart disease</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Hypertensive_nephropathy" title="Hypertensive nephropathy">Hypertensive nephropathy</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Secondary_hypertension" title="Secondary hypertension">Secondary hypertension</a> (<a href="/wiki/Renovascular_hypertension" title="Renovascular hypertension">Renovascular hypertension</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Pulmonary_hypertension" title="Pulmonary hypertension">Pulmonary hypertension</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Malignant_hypertension" title="Malignant hypertension">Malignant hypertension</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Benign_hypertension" title="Benign hypertension">Benign hypertension</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Systolic_hypertension" title="Systolic hypertension">Systolic hypertension</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/White_coat_hypertension" title="White coat hypertension">White coat hypertension</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: MistyRose;">
<div style="padding:0em 0.75em;"><a href="/wiki/Hypotension" title="Hypotension">Hypotension</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Orthostatic_hypotension" title="Orthostatic hypotension">Orthostatic hypotension</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i>See also <a href="/wiki/Template:Congenital_vascular_defects" title="Template:Congenital vascular defects">congenital</a>, <a href="/wiki/Template:Vascular_tumors" title="Template:Vascular tumors">neoplasia</a></i></div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Preprocessor node count: 29553/1000000
Post-expand include size: 325923/2048000 bytes
Template argument size: 137916/2048000 bytes
Expensive parser function count: 1/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:85385-0!1!0!default!!en!2 and timestamp 20090403204520 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Atherosclerosis">http://en.wikipedia.org/wiki/Atherosclerosis</a>"</div>
			<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="/wiki/Category:Cardiovascular_diseases" title="Category:Cardiovascular diseases">Cardiovascular diseases</a></span> | <span dir='ltr'><a href="/wiki/Category:Angiology" title="Category:Angiology">Angiology</a></span> | <span dir='ltr'><a href="/wiki/Category:Cardiology" title="Category:Cardiology">Cardiology</a></span></div><div id="mw-hidden-catlinks" class="mw-hidden-cats-hidden">Hidden categories:&#32;<span dir='ltr'><a href="/wiki/Category:Pages_with_DOIs_broken_since_2008" title="Category:Pages with DOIs broken since 2008">Pages with DOIs broken since 2008</a></span> | <span dir='ltr'><a href="/wiki/Category:Pages_with_DOIs_broken_since_2009" title="Category:Pages with DOIs broken since 2009">Pages with DOIs broken since 2009</a></span> | <span dir='ltr'><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_unsourced_statements_since_October_2008" title="Category:Articles with unsourced statements since October 2008">Articles with unsourced statements since October 2008</a></span></div></div>			<!-- end content -->
						<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
	
				 <li id="ca-nstab-main" class="selected"><a href="/wiki/Atherosclerosis" title="View the content page [c]" accesskey="c">Article</a></li>
				 <li id="ca-talk"><a href="/wiki/Talk:Atherosclerosis" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
				 <li id="ca-edit"><a href="/w/index.php?title=Atherosclerosis&amp;action=edit" title="You can edit this page. &#10;Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
				 <li id="ca-history"><a href="/w/index.php?title=Atherosclerosis&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>			</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Atherosclerosis" title="You are encouraged to log in; however, it is not mandatory. [o]" accesskey="o">Log in / create account</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(http://upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
	<div class='generated-sidebar portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
				<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content — the best of Wikipedia">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
	<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/w/index.php" id="searchform"><div>
				<input type='hidden' name="title" value="Special:Search"/>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search Wikipedia for this text" />
			</div></form>
		</div>
	</div>
	<div class='generated-sidebar portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Atherosclerosis" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Atherosclerosis" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Atherosclerosis&amp;printable=yes" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Atherosclerosis&amp;oldid=281569196" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Atherosclerosis&amp;id=281569196">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-ar"><a href="http://ar.wikipedia.org/wiki/%D8%AA%D8%B5%D9%84%D8%A8_%D8%B9%D8%B5%D9%8A%D8%AF%D9%8A">العربية</a></li>
				<li class="interwiki-az"><a href="http://az.wikipedia.org/wiki/Ateroskleroz">Azərbaycan</a></li>
				<li class="interwiki-bs"><a href="http://bs.wikipedia.org/wiki/Ateroskleroza">Bosanski</a></li>
				<li class="interwiki-bg"><a href="http://bg.wikipedia.org/wiki/%D0%90%D1%82%D0%B5%D1%80%D0%BE%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7%D0%B0">Български</a></li>
				<li class="interwiki-cs"><a href="http://cs.wikipedia.org/wiki/Ateroskler%C3%B3za">Česky</a></li>
				<li class="interwiki-da"><a href="http://da.wikipedia.org/wiki/%C3%85reforkalkning">Dansk</a></li>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Arteriosklerose">Deutsch</a></li>
				<li class="interwiki-el"><a href="http://el.wikipedia.org/wiki/%CE%91%CF%81%CF%84%CE%B7%CF%81%CE%B9%CE%BF%CF%83%CE%BA%CE%BB%CE%AE%CF%81%CF%85%CE%BD%CF%83%CE%B7">Ελληνικά</a></li>
				<li class="interwiki-es"><a href="http://es.wikipedia.org/wiki/Ateroesclerosis">Español</a></li>
				<li class="interwiki-fa"><a href="http://fa.wikipedia.org/wiki/%D8%A2%D8%AA%D8%B1%D9%88%D8%A7%D8%B3%DA%A9%D9%84%D8%B1%D9%88%D8%B3%DB%8C%D8%B3">فارسی</a></li>
				<li class="interwiki-ko"><a href="http://ko.wikipedia.org/wiki/%EB%8F%99%EB%A7%A5%EA%B2%BD%ED%99%94%EC%A6%9D">한국어</a></li>
				<li class="interwiki-is"><a href="http://is.wikipedia.org/wiki/%C3%86%C3%B0ak%C3%B6lkun">Íslenska</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Aterosclerosi">Italiano</a></li>
				<li class="interwiki-he"><a href="http://he.wikipedia.org/wiki/%D7%98%D7%A8%D7%A9%D7%AA_%D7%A2%D7%95%D7%A8%D7%A7%D7%99%D7%9D">עברית</a></li>
				<li class="interwiki-ka"><a href="http://ka.wikipedia.org/wiki/%E1%83%90%E1%83%97%E1%83%94%E1%83%A0%E1%83%9D%E1%83%A1%E1%83%99%E1%83%9A%E1%83%94%E1%83%A0%E1%83%9D%E1%83%96%E1%83%98">ქართული</a></li>
				<li class="interwiki-nl"><a href="http://nl.wikipedia.org/wiki/Atheromatose">Nederlands</a></li>
				<li class="interwiki-ja"><a href="http://ja.wikipedia.org/wiki/%E5%8B%95%E8%84%88%E7%A1%AC%E5%8C%96%E7%97%87">日本語</a></li>
				<li class="interwiki-no"><a href="http://no.wikipedia.org/wiki/%C3%85reforkalkning">‪Norsk (bokmål)‬</a></li>
				<li class="interwiki-pl"><a href="http://pl.wikipedia.org/wiki/Mia%C5%BCd%C5%BCyca">Polski</a></li>
				<li class="interwiki-pt"><a href="http://pt.wikipedia.org/wiki/Aterosclerose">Português</a></li>
				<li class="interwiki-qu"><a href="http://qu.wikipedia.org/wiki/Sirk%27a_iskuyay">Runa Simi</a></li>
				<li class="interwiki-ru"><a href="http://ru.wikipedia.org/wiki/%D0%90%D1%82%D0%B5%D1%80%D0%BE%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7">Русский</a></li>
				<li class="interwiki-sr"><a href="http://sr.wikipedia.org/wiki/Ateroskleroza">Српски / Srpski</a></li>
				<li class="interwiki-fi"><a href="http://fi.wikipedia.org/wiki/Ateroskleroosi">Suomi</a></li>
				<li class="interwiki-sv"><a href="http://sv.wikipedia.org/wiki/%C3%85derf%C3%B6rkalkning">Svenska</a></li>
				<li class="interwiki-tr"><a href="http://tr.wikipedia.org/wiki/Ateroskleroz">Türkçe</a></li>
				<li class="interwiki-uk"><a href="http://uk.wikipedia.org/wiki/%D0%90%D1%82%D0%B5%D1%80%D0%BE%D1%81%D0%BA%D0%BB%D0%B5%D1%80%D0%BE%D0%B7">Українська</a></li>
				<li class="interwiki-zh"><a href="http://zh.wikipedia.org/wiki/%E5%8A%A8%E8%84%89%E7%A1%AC%E5%8C%96">中文</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
					<li id="lastmod"> This page was last modified on 3 April 2009, at 20:45.</li>
					<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc.</a>, a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
					<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
					<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
					<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
</div>

		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
<!-- Served by srv54 in 0.135 secs. --></body></html>
